During this weekend, have met in Seville the best European specialists of different medical specialties in allergy, internal medicine, dermatology and emergency care to share their knowledge of angioedema, a disease that can cause death and that is underdiagnosed, as has been discussed these experts. In addition, patients affected by this pathology have also attended some of these days-urgently require access to new drugs that are present in Spain since by bureaucratic fear they will not have easy access to medication and have reported that during the past two months, have felt totally helpless.
● The experts reveal that Spain has been one of those European countries that has received a grant to investigate this complex disease that has three variants and is usually confused with an allergy. European specialists have explained in these days that is necessary to train the earliest health professionals in the diagnosis and treatment of this disease are currently analyzing the genetic causes of the three subtypes (Type I, II and III).
● This condition is underdiagnosed and only 45% of patients across Europe are correctly diagnosed and treated, according to Dr. Marco said Cicardi, Head of the Unit of Internal Medicine Hospital Luigi Sacco, Italy.
● Angioedema is a serious disease that affects an estimated 1/10.000 or 1:50,000 individuals worldwide. This means only the European Union may have 75,000 people who are affected by this disease. There are many people who suffer from GAD at some point in their lives and are unaware they have it, because it usually coincides with an allergy sporadic, as there are patients who may have few episodes throughout life.
● These inflammatory episodes may occur independently or together in the glottis, face, mucous, abdomen, limbs or internal organs like the appendix or bowel. These inflammatory processes are very serious and sometimes can be confused with other allergic diseases. There are patients who have been slow to diagnose the disease twenty years and have always thought they were allergic.
Angioedema is an underdiagnosed disease and is estimated to affect one in 10,000 to 50,000 patients in Europe and USA. Currently, only 45% of people suffering from this disease in Europe are correctly diagnosed and treated, said Marco Cicardi, Head of the Unit of Internal Medicine Hospital Luigi Sacco, Italy, in a conference held during this weekend Virgen del Rocio Hospital in Seville and have participated in the great references from all over Europe in different fields as Allergology, Internal Medicine, Emergency, Dermatology and Genetics.
These specialists have also highlighted the presence of Dr. Konrad Bork, a researcher at the Department of Dermatology, University of Mainz, Dr. S. Cichon, Researcher Geneticist Genomics, Department of Brain Center, University of Bonn, Germany and Dr. H. Professor Farkas Semmelweiss University, Budapest, Hungary; all coordinators of multiple research projects on this disease and other inflammatory-based diseases.
By Spain, has highlighted the presence of Dr. Teresa Gonzalez-Quevedo Tejerina, an allergist at the Hospital Virgen del Rocío de Sevilla, who has stated that, currently in Spain, there are about 800 families diagnosed, of which 206 belong to Andalusia and has alerted his colleagues that doctors surely there are many more families without a diagnosis in our country, because this disease in some of its subtypes as in the class II and III-often mistaken for an episode of allergy time. The aim of this conference is to train all possible medical specialists in knowledge, diagnosis and treatment of this disease as hereditary angioedema is an underdiagnosed disease not uncommon, because many people who suffer and do not know that the suffer and therefore is of low prevalence, Gonzalez-Quevedo said.
This view was shared by other specialists. For his part, Dr. Mark Cicardi said Europe is ahead in the investigation of this disease thanks to European Union aid. Spain is one of ten European countries that have received EU subsidies in recent years to investigate Angioedema with Italy, Denmark, France, Germany, Norway, Poland, Switzerland and United Kingdom. Therefore, Dr. Cicardi revealed that, thanks to these aids are created in Spain hospital groups of researchers and reference in the diagnosis and treatment of this disease. In Europe we have a unique opportunity to advance in the genetic diagnosis of this disease in the U.S. and, therefore, to prevent many deaths and episodes of angioedema. And, he added, "It is necessary to train medical specialists in allergy, immunology, pulmonology, internal medicine, otolaryngology, gastrointestinal specialists and nephrology at the correct diagnosis of this disease, because many bodies may be affected sporadically and not angioedema necessarily have to be present at all, said the Italian internist.
Dr. Gonzalez-Quevedo Tejerina Seville, said that in severe cases the disease can trigger critical tables to ignite the glottis, pharynx, or certain parts of the respiratory system can potentially have a fatal outcome for the patient. Fortunately, we have the good fortune to be able to diagnose this disease with new genetic markers and dealing with new treatments. Diagnose addition we need access to more training on the different therapeutic options with which we have and when to apply depending on the type of patient and emerging new scientific advances that help us to better therapeutic targets, reiterated this Doctor of the Hospital Virgen del Rocio.
As pointed out by Dr. Sven Cichon, Assistant Professor of Human Genetics at the Institute of Human Genetics at the Life and Brain Center, University of Bonn, Germany, one of the reasons for this underdiagnosis has been the difficulty of the when classifying subtypes within the disease, since there are three types of hereditary angioedema. Hereditary angioedema type I, type II hereditary angioedema and hereditary angioedema type III. For this doctor, patients with type I, presented in its analytical shortcomings in the protein called C1 inhibitor estarasa and also observed a mutation on chromosome 11. In the class II Angioedema, C1 levels inhibor are correct, but this enzyme does not perform its function properly and is usually observed a mutation on chromosome 12. Finally, the angioedema type III, C1 inhibitor levels are normal, and the rest of the chromosomes without mutations occur, but it is believed that this subtype III is hormone-dependent, ie it is related to estrogen level in the patient and specifically in this subclass, the German experts in genetics, are perhaps studying a possible mutation on chromosome 5 in this subtype.
Self-care information program
Anyway, in the three types of angioedema disease can be fatal in some of the episodes and it is necessary to diagnose it early and take preventive measures to prevent such crises and involving patients in self-management programs that do not live with panic, pinpointed all the experts present.
In the words of Dr. Gonzalez-Quevedo, the type III hereditary angioedema are the most difficult to classify and are often confused with a specific allergy to a substance. Therefore, any person who has suffered an episode of angioedema in their life should ask to be carried out appropriate tests to rule out suffering any of the three existing types of hereditary angioedema and participate as far as possible in their self-serving a series of recommendations to prevent one of these attacks, said the doctor.
Affected patients speak
Commenting on the magic word self-care, some patients suffering from these ailments value expressed their opinion in open to specialists. We are afraid of not having the medication on time, since we know that the EMEA has approved new drugs but in some hospitals in Spain, for various reasons, still do not. Then, "We are afraid of suffering a serious crisis and we can not treat. Faced with a serious crisis of angioedema we only have two drugs, one of them is alien to medicine that involves red tape and the other, Firazyr is not yet in many hospitals. I was not prepared to live in fear and before I decided to get my personal situation in Germany and now I'm much calmer, said Mercedes Blanco, patients with this condition.
Given these statements, Dr. Teresa Gonzalez-Quevedo and Dr. Stefan Cimbollek, both members of the Department of Allergology Hospital Virgen del Rocío explained to patients who expected this situation will be normalized since May, hope that very soon our Departments hospital pharmacy help us process all necessary steps to have all the resources possible battery which already exist in Spain to deal a serious crisis in patients with hereditary angioedema, argued these doctors.
As noted by the team of Angioedema in Italy, this new active ingredient, Icatibant acetate will be presented as a prefilled syringe and represents a revolution in the fast approach to this condition, because being a synthetic substance reduces the risks, as such as infections, involving far plasma derivatives injected intravenously. This is a simple subcutaneous injection under the skin-much easier to make and early relief of symptoms occurs in a median time of 48 minutes, which will revolutionize patient self-care, said Cicardi.
Then the group of patients from Andalusia in relation to these statements by experts, proposed the idea of creating a group of self-care of patients with allergies belonging exclusively to the zone of Andalucía. Idea which was warmly welcomed by most of the specialists who were present and which inspired a new political issue as to the responsibilities of each community and government aid to deliver only the entities belonging to their community, rather than give them to the national office. I do not agree that local groups are created on this disease, because we must be together in one country, and it seems unfair that just because we divide the given economic aid each Autonomous Community. If we are divided we lose strength because each pull to one side as is already happening at other levels in Spain, said Sara Smith, President of the Spanish Association of Patients with Hereditary Angioedema Familiar.
Friday, August 28, 2009
About 400 women from Bizkaia have controlled pregnancy and pregnancy Psicofármacos Unit of the Psychiatric Service of Hospital de Cruces.
About 400 women from Bizkaia have controlled pregnancy and pregnancy Psicofármacos Unit of the Psychiatric Service of Hospital de Cruces.
The Unit has not detected by use of psychotropic medication problems beyond the normal casuistry, which expresses the guarantee offered maintenance treatment under control.
The Psychoactive Drugs and Pregnancy Unit of the Psychiatric Service of Hospital de Cruces which coordinates Robador Ana psychiatrist has, since 2000, the date of its foundation in a referral center for women who want to stay or have become pregnant suffer mental pathology. Over the past eight years around 400 women have taken the course of her pregnancy under close monitoring of that unit, immersed in the category of pathological pregnancies and the interaction of various specialists. It is the best way to control the whole process, says the coordinator of the Unit, Psychiatry Service dependent but closely related, in turn, with the Department of Obstetrics and Gynecology and Neonatology of the Hospital.
In these and other issues Robador Ana speech at the conference's closing day organized by the extraordinary Basque-Navarra of Psychiatry. Throughout this period, the Unit has not encountered problems by use of psychotropic medication beyond the normal casuistry, which expresses the guarantee offered maintenance treatment under control. Ana Robador said, though, that when it can not all cases seen are of the same gravity-medication is recommended as little as possible in the first trimester of pregnancy.
It is a simple matter. Many patients come to the Hospital de Cruces derived from other schools and when they are pregnant. Perhaps not noticed the pregnancy until after the first month and during this period have been medicated. That is why the unit has begun to recommend pregnancy planning to withdraw the drugs of greatest risk.
Ana Robador emphasizes that not all cases treated in the unit due to severe psychiatric disorders, which are those that require closer monitoring. There are also women who have, for example, moderate anxiety disorders that require specific monitoring of her pregnancy.
The Unit has not detected by use of psychotropic medication problems beyond the normal casuistry, which expresses the guarantee offered maintenance treatment under control.
The Psychoactive Drugs and Pregnancy Unit of the Psychiatric Service of Hospital de Cruces which coordinates Robador Ana psychiatrist has, since 2000, the date of its foundation in a referral center for women who want to stay or have become pregnant suffer mental pathology. Over the past eight years around 400 women have taken the course of her pregnancy under close monitoring of that unit, immersed in the category of pathological pregnancies and the interaction of various specialists. It is the best way to control the whole process, says the coordinator of the Unit, Psychiatry Service dependent but closely related, in turn, with the Department of Obstetrics and Gynecology and Neonatology of the Hospital.
In these and other issues Robador Ana speech at the conference's closing day organized by the extraordinary Basque-Navarra of Psychiatry. Throughout this period, the Unit has not encountered problems by use of psychotropic medication beyond the normal casuistry, which expresses the guarantee offered maintenance treatment under control. Ana Robador said, though, that when it can not all cases seen are of the same gravity-medication is recommended as little as possible in the first trimester of pregnancy.
It is a simple matter. Many patients come to the Hospital de Cruces derived from other schools and when they are pregnant. Perhaps not noticed the pregnancy until after the first month and during this period have been medicated. That is why the unit has begun to recommend pregnancy planning to withdraw the drugs of greatest risk.
Ana Robador emphasizes that not all cases treated in the unit due to severe psychiatric disorders, which are those that require closer monitoring. There are also women who have, for example, moderate anxiety disorders that require specific monitoring of her pregnancy.
refresher course in ophthalmology
Fernandez-Vega Institute will present its third professionals engaged in the research phase for a refresher course in ophthalmology.
Prestigious ophthalmologists attend this conference to be held on 8 and 9 May. Know the new facilities and will make a major update on solutions to major eye diseases.
Following the recent opening of the third institutional phase Fernández-Vega Ophthalmological Institute by Their Majesties King, the center will host the next days 8 and 9 May, a Refresher Course in Ophthalmology, congress will present to the ophthalmologists new facilities dedicated to basic research. The meeting, which will serve its audience to catch up on the major advances achieved in recent years in all or almost all ophthalmic disciplines, will also address important issues that already begun research in the center, including new techniques and treatment of glaucoma and other diseases common in the cornea and retina.
The course, attended by two hundred experts from around the world, is led by Professor Luis Fernández-Vega Sanz, director of the Eye Institute, and is divided into the following six sessions (led by doctors at each of them are listed ) Supeficie eye (doctors and Begoña Baamonde Jesus Merayo Arbaiza) Cornea and refractive (José F. Alfonso Sanchez and Mariano Sanchez Yllera), Cataract (Luis Fernández-Vega Sanz and Jose I. Blázquez García), Orbit and appendages (Javier Fernandez -Vega Sanz), Glaucoma (Pedro Pablo Martín and Manuel Calvo Riano Granero) and Retina (Álvaro Fernández-Vega Sanz).
Institute director, Luis Fernández-Vega Sanz, considered appropriate that the opening of the third phase had not only some institutional (or social) but held a medical activity that would serve, in turn, to present to the world of Medicine is pioneering basic research unit in Europe in which they have invested six million euros and which employs more than twenty internationally renowned specialists.
Six working sessions
The first session (Supeficie eye) will try to update the most common problems of the ocular surface, such as dry eye or ocular allergies, which cause discomfort (feeling of sand, stinging, itching) and can reduce vision and affect the quality of life of patients and more rare diseases such as ocular manifestations of systemic diseases such as rheumatic or immunological. It will review the prevention, medical and surgical treatment and regenerative medicine will address the ocular surface with the update of transplantation techniques and reconstruction of the cornea, eyelids and conjunctiva.
The second (Cornea and Refractive) address laser surgical techniques and intraocular lenses. On the latter must be said that existing lenses that correct presbyopia and any other defect of graduation. Of them should also highlight that ICLs phakic lenses and can correct most refractive errors: myopia, hipermetromía, astigmatism, etc.. Previously, only solved the first. It is indicated for patients unable to tolerate the laser.
The third meeting (Waterfall), will display new bifocals will present Luis Fernández-Vega Sanz. These lenses improvements to existing ones because they produce better intermediate vision. Also present at this meeting lenses (IOLs) with adjustable light.
The fourth session (Orbit and appendages) will focus on major developments on practical techniques in Ocular Plastic Surgery. Keep in mind that cosmetic surgery that is practiced today in most Western countries are related in a direct way with the eyes, especially the eyelids, orbits and tear ducts.
About Glaucoma (fifth session) will be discussed in depth on the new tools for early diagnosis of the disease (one of the main works to be carried out in the basic research unit of the Institute). It will also address new and better surgical techniques and implants perforating sclerectomy not valvular in glaucoma treatment.
In the last session (Retina) will discuss the progress made in recent years to resolve the macular degeneration associated with age, which is the leading cause of blindness in people over 60 years, which affects, from this age to 7% of world population.
Prestigious ophthalmologists attend this conference to be held on 8 and 9 May. Know the new facilities and will make a major update on solutions to major eye diseases.
Following the recent opening of the third institutional phase Fernández-Vega Ophthalmological Institute by Their Majesties King, the center will host the next days 8 and 9 May, a Refresher Course in Ophthalmology, congress will present to the ophthalmologists new facilities dedicated to basic research. The meeting, which will serve its audience to catch up on the major advances achieved in recent years in all or almost all ophthalmic disciplines, will also address important issues that already begun research in the center, including new techniques and treatment of glaucoma and other diseases common in the cornea and retina.
The course, attended by two hundred experts from around the world, is led by Professor Luis Fernández-Vega Sanz, director of the Eye Institute, and is divided into the following six sessions (led by doctors at each of them are listed ) Supeficie eye (doctors and Begoña Baamonde Jesus Merayo Arbaiza) Cornea and refractive (José F. Alfonso Sanchez and Mariano Sanchez Yllera), Cataract (Luis Fernández-Vega Sanz and Jose I. Blázquez García), Orbit and appendages (Javier Fernandez -Vega Sanz), Glaucoma (Pedro Pablo Martín and Manuel Calvo Riano Granero) and Retina (Álvaro Fernández-Vega Sanz).
Institute director, Luis Fernández-Vega Sanz, considered appropriate that the opening of the third phase had not only some institutional (or social) but held a medical activity that would serve, in turn, to present to the world of Medicine is pioneering basic research unit in Europe in which they have invested six million euros and which employs more than twenty internationally renowned specialists.
Six working sessions
The first session (Supeficie eye) will try to update the most common problems of the ocular surface, such as dry eye or ocular allergies, which cause discomfort (feeling of sand, stinging, itching) and can reduce vision and affect the quality of life of patients and more rare diseases such as ocular manifestations of systemic diseases such as rheumatic or immunological. It will review the prevention, medical and surgical treatment and regenerative medicine will address the ocular surface with the update of transplantation techniques and reconstruction of the cornea, eyelids and conjunctiva.
The second (Cornea and Refractive) address laser surgical techniques and intraocular lenses. On the latter must be said that existing lenses that correct presbyopia and any other defect of graduation. Of them should also highlight that ICLs phakic lenses and can correct most refractive errors: myopia, hipermetromía, astigmatism, etc.. Previously, only solved the first. It is indicated for patients unable to tolerate the laser.
The third meeting (Waterfall), will display new bifocals will present Luis Fernández-Vega Sanz. These lenses improvements to existing ones because they produce better intermediate vision. Also present at this meeting lenses (IOLs) with adjustable light.
The fourth session (Orbit and appendages) will focus on major developments on practical techniques in Ocular Plastic Surgery. Keep in mind that cosmetic surgery that is practiced today in most Western countries are related in a direct way with the eyes, especially the eyelids, orbits and tear ducts.
About Glaucoma (fifth session) will be discussed in depth on the new tools for early diagnosis of the disease (one of the main works to be carried out in the basic research unit of the Institute). It will also address new and better surgical techniques and implants perforating sclerectomy not valvular in glaucoma treatment.
In the last session (Retina) will discuss the progress made in recent years to resolve the macular degeneration associated with age, which is the leading cause of blindness in people over 60 years, which affects, from this age to 7% of world population.
ASEFARMA pharmacists report on the swine flu.
Asefarma, together with pharmacies in Madrid, has produced a brochure to advise anyone who has doubts Cities @.
With this initiative seek to collaborate for the hospital emergency room or not to collapse before the pandemic alert
Information is the best recipe to prevent. Therefore, in the 300 pharmacies in Madrid ASEFARMA attached, the main Pharmacy Consulting Spain, has just been put in place an action that will relieve more than one. Our pharmacists will provide information to any citizen who has questions about what this virus and what to do, says Carlos Garcia-Mauriño, managing partner of Asefarma. In this way we transmit to society calm and Spanish health authorities have demonstrated their expertise and have all the control mechanisms to quickly identify and monitor cases of people affected, he adds.
And the possibility is that, as recently announced by WHO (World Health Organization) of a global pandemic, the work of pharmacies reveals fundamental. First because of its proximity to the citizen virtually the entire population is a pharmacy within 300 meters from his home, second as a clearinghouse for antiviral drugs etc, and third as health professionals in informing and advising. The current law governing pharmacies in Spain and its conception as part of our National Health System angels are revealed in these times of uncertainty, added Garcia-Maurin.
This being the pharmacists will place special emphasis on explaining that the drugs needed to kill the virus are the same as those used in typical flu. These antivirals have side effects that are only released with a prescription.
As for the doubts that the pharmacists will clear to citizens that they will want to attend, including:
- What is the swine flu and how is it spread?
- Are the swine influenza virus can infect humans?
- What are the symptoms?
- Does the swine influenza virus H1N1 is equal to the H1N1 influenza virus in humans?
- How is diagnosed swine flu infections in humans?
- Is the current vaccine protects against seasonal influenza flu type H1N1 porcine origin?
- Are there medicines to treat people infected with swine influenza viruses?
- What is done to detect other cases of infections in people with the virus H1N1 swine influenza once it has detected a case?
On the other hand since it Asefarma advised in pharmacies where masks to protect themselves from acquiring 100% of viruses - and they are the same ones that are already spreading in hospitals, since they, not others be purchased in other shops, meet European standards for which they are made and are proof of sneezing, socio-end Asefarma director.
With this initiative seek to collaborate for the hospital emergency room or not to collapse before the pandemic alert
Information is the best recipe to prevent. Therefore, in the 300 pharmacies in Madrid ASEFARMA attached, the main Pharmacy Consulting Spain, has just been put in place an action that will relieve more than one. Our pharmacists will provide information to any citizen who has questions about what this virus and what to do, says Carlos Garcia-Mauriño, managing partner of Asefarma. In this way we transmit to society calm and Spanish health authorities have demonstrated their expertise and have all the control mechanisms to quickly identify and monitor cases of people affected, he adds.
And the possibility is that, as recently announced by WHO (World Health Organization) of a global pandemic, the work of pharmacies reveals fundamental. First because of its proximity to the citizen virtually the entire population is a pharmacy within 300 meters from his home, second as a clearinghouse for antiviral drugs etc, and third as health professionals in informing and advising. The current law governing pharmacies in Spain and its conception as part of our National Health System angels are revealed in these times of uncertainty, added Garcia-Maurin.
This being the pharmacists will place special emphasis on explaining that the drugs needed to kill the virus are the same as those used in typical flu. These antivirals have side effects that are only released with a prescription.
As for the doubts that the pharmacists will clear to citizens that they will want to attend, including:
- What is the swine flu and how is it spread?
- Are the swine influenza virus can infect humans?
- What are the symptoms?
- Does the swine influenza virus H1N1 is equal to the H1N1 influenza virus in humans?
- How is diagnosed swine flu infections in humans?
- Is the current vaccine protects against seasonal influenza flu type H1N1 porcine origin?
- Are there medicines to treat people infected with swine influenza viruses?
- What is done to detect other cases of infections in people with the virus H1N1 swine influenza once it has detected a case?
On the other hand since it Asefarma advised in pharmacies where masks to protect themselves from acquiring 100% of viruses - and they are the same ones that are already spreading in hospitals, since they, not others be purchased in other shops, meet European standards for which they are made and are proof of sneezing, socio-end Asefarma director.
Experts warn of consumer confusion generated by the continuous changes in nutrition messages.
Foundation Health Sciences, Instituto Tomás Pascual and Student Residence managing the Day of obesity to anorexia: controversies in current food
Food is being used almost as drugs-especially-called functional, so it would not hurt that these were all the healing properties attributed to them
The Mediterranean diet has shifted from largely unknown to become a panacea, although few studies with scientific evidence of its potential beneficial effects
Dissatisfaction with self-image arises primarily from the enormous social pressure and especially affects women
The generic communication and non-commercial training should only be done by government and academia, but also by agents of the Food Chain
There are bodies concerned in accordance with criteria that we feed upon them well, and not on what one should decide autonomously
What to eat? Today is the question that we do very often, when surrounded by palatable foods cheaper and easier to obtain, due to the uncertainty of whether they are good or bad, ie if we help to maintain health or, conversely, we ill will. Never before have we had so much information and at the time, so much confusion.
The food itself has ceased to be a natural to become very sophisticated that can be used in many ways, said Dr. Susana Monereo, Chief of Endocrinology and Nutrition Service of the Hospital de Getafe (Madrid) during the journey from obesity to anorexia: current controversies in food, organized by the Foundation for Health Sciences, Instituto Tomás Pascual Sanz and the Residencia de Estudiantes.
Using food wrongly by overinformation or lack of it, just taking a toll on our health in many ways, explains Monereo. In this regard, one of the objectives of the day, held today at the Residencia de Estudiantes, is to highlight the important role that food plays in our lives. Food is being used almost as drugs-especially-called functional, so it would not hurt that these were all the healing properties attributed to them, he adds.
According to Professor Gregorio Varela, Professor of Nutrition and Food Science, University CEU San Pablo, and president of the Spanish Nutrition Foundation, despite the advances in our knowledge, no other science-an allusion to nutrition, which is more surrounded by beliefs, myths and magic. During his lecture, entitled Truths and fallacies about the power of food, the expert had expressed surprise that such things happen more now than a hundred years ago.
The constant modification of the nutritional message in recent years has generated many times, mislead the consumer, explains Professor Varela. For example, the Mediterranean diet has gone from being a stranger to become a panacea, although few studies that show scientific evidence of its potential beneficial effects, he adds. Olive oil, fish and wine are some foods whose virtues have been globalized.
For his part, Dr. Clotilde Vazquez, head of the Clinical Nutrition Section of the Hospital Ramon y Cajal, Madrid, said that under eating disorders ranging from obesity to anorexia lies an abnormal relationship with food. They have a significant genetic basis, although dissatisfaction with the self-image arises primarily from the enormous social pressure, which particularly affects women, he notes.
Following this, young people are too drastic dieting. An exaggerated caloric restriction predisposes the organism to a subsequent rebound, which usually gain more weight than they lost and more fat, says the expert. Worryingly, increasingly, obesity is reached from the desire to lose weight, says Dr. Vazquez. Balance is in the normalization of the image as something quite different, not subject to external charges, and the improvement of the relationship with food.
Regarding the reliability of information and communication on food, José Ignacio Arranz, Interalimentario CEO Forum, a nonprofit association formed by 14 leading food companies, and former executive director of the Spanish Agency for Food Security and Nutrition has stressed the need to inform and educate the society on business communication, truth, excellence and scientific support.
During his lecture, entitled The information and communication on food, Arranz communication has suggested that generic non-commercial training and should only be done by government and academia, but also have to engage the operators of the food chain. In this sense, it is clear that businesses or business associations that come will be less challenged and the better your profile and increased its record of excellence, he concludes.
The ethical aspect of dietetics has been commissioned Professor Diego Gracia, Professor of History of Medicine at the Complutense University of Madrid and president of the Foundation for Health Sciences. There are many bodies involved in that nourish us according to criteria that suits them, and not on what one should make independent decisions, says the expert.
Professor Grace said that when the supply of products is so large, it is necessary to promote truthful reporting and accountability in the election: only mature personalities make the right decisions to get such a broad range of possibilities.
Tomás Pascual Sanz Institute for Nutrition and Health
Tomás Pascual Sanz Institute for Nutrition and Health is a non-profit organization created to promote research and training in the field of health and nutrition. Among others, are objectives of the Institute Tomás Pascual Sanz clinical research, collaboration with public authorities in nutritional programs, grants offered by scientific research, through agreements with various universities and the promotion of Environmental Management studies.
http://www.institutotomaspascual.es/
Foundation Health Sciences
Foundation Health Sciences is a nonprofit institution that seeks to be a meeting place for different social sectors involved in the world of health. Founded in 1991, its priority objectives revolve around bioethics, health, science and humanities, with a broad range of activities and projects.
Food is being used almost as drugs-especially-called functional, so it would not hurt that these were all the healing properties attributed to them
The Mediterranean diet has shifted from largely unknown to become a panacea, although few studies with scientific evidence of its potential beneficial effects
Dissatisfaction with self-image arises primarily from the enormous social pressure and especially affects women
The generic communication and non-commercial training should only be done by government and academia, but also by agents of the Food Chain
There are bodies concerned in accordance with criteria that we feed upon them well, and not on what one should decide autonomously
What to eat? Today is the question that we do very often, when surrounded by palatable foods cheaper and easier to obtain, due to the uncertainty of whether they are good or bad, ie if we help to maintain health or, conversely, we ill will. Never before have we had so much information and at the time, so much confusion.
The food itself has ceased to be a natural to become very sophisticated that can be used in many ways, said Dr. Susana Monereo, Chief of Endocrinology and Nutrition Service of the Hospital de Getafe (Madrid) during the journey from obesity to anorexia: current controversies in food, organized by the Foundation for Health Sciences, Instituto Tomás Pascual Sanz and the Residencia de Estudiantes.
Using food wrongly by overinformation or lack of it, just taking a toll on our health in many ways, explains Monereo. In this regard, one of the objectives of the day, held today at the Residencia de Estudiantes, is to highlight the important role that food plays in our lives. Food is being used almost as drugs-especially-called functional, so it would not hurt that these were all the healing properties attributed to them, he adds.
According to Professor Gregorio Varela, Professor of Nutrition and Food Science, University CEU San Pablo, and president of the Spanish Nutrition Foundation, despite the advances in our knowledge, no other science-an allusion to nutrition, which is more surrounded by beliefs, myths and magic. During his lecture, entitled Truths and fallacies about the power of food, the expert had expressed surprise that such things happen more now than a hundred years ago.
The constant modification of the nutritional message in recent years has generated many times, mislead the consumer, explains Professor Varela. For example, the Mediterranean diet has gone from being a stranger to become a panacea, although few studies that show scientific evidence of its potential beneficial effects, he adds. Olive oil, fish and wine are some foods whose virtues have been globalized.
For his part, Dr. Clotilde Vazquez, head of the Clinical Nutrition Section of the Hospital Ramon y Cajal, Madrid, said that under eating disorders ranging from obesity to anorexia lies an abnormal relationship with food. They have a significant genetic basis, although dissatisfaction with the self-image arises primarily from the enormous social pressure, which particularly affects women, he notes.
Following this, young people are too drastic dieting. An exaggerated caloric restriction predisposes the organism to a subsequent rebound, which usually gain more weight than they lost and more fat, says the expert. Worryingly, increasingly, obesity is reached from the desire to lose weight, says Dr. Vazquez. Balance is in the normalization of the image as something quite different, not subject to external charges, and the improvement of the relationship with food.
Regarding the reliability of information and communication on food, José Ignacio Arranz, Interalimentario CEO Forum, a nonprofit association formed by 14 leading food companies, and former executive director of the Spanish Agency for Food Security and Nutrition has stressed the need to inform and educate the society on business communication, truth, excellence and scientific support.
During his lecture, entitled The information and communication on food, Arranz communication has suggested that generic non-commercial training and should only be done by government and academia, but also have to engage the operators of the food chain. In this sense, it is clear that businesses or business associations that come will be less challenged and the better your profile and increased its record of excellence, he concludes.
The ethical aspect of dietetics has been commissioned Professor Diego Gracia, Professor of History of Medicine at the Complutense University of Madrid and president of the Foundation for Health Sciences. There are many bodies involved in that nourish us according to criteria that suits them, and not on what one should make independent decisions, says the expert.
Professor Grace said that when the supply of products is so large, it is necessary to promote truthful reporting and accountability in the election: only mature personalities make the right decisions to get such a broad range of possibilities.
Tomás Pascual Sanz Institute for Nutrition and Health
Tomás Pascual Sanz Institute for Nutrition and Health is a non-profit organization created to promote research and training in the field of health and nutrition. Among others, are objectives of the Institute Tomás Pascual Sanz clinical research, collaboration with public authorities in nutritional programs, grants offered by scientific research, through agreements with various universities and the promotion of Environmental Management studies.
http://www.institutotomaspascual.es/
Foundation Health Sciences
Foundation Health Sciences is a nonprofit institution that seeks to be a meeting place for different social sectors involved in the world of health. Founded in 1991, its priority objectives revolve around bioethics, health, science and humanities, with a broad range of activities and projects.
Treatment with zoledronic acid reduced the risk of relapse in women with breast cancer.
According to the results derived from this research zoledronic acid treatment would avoid the recurrence of breast cancer and 800 women in Spain every year
In Spain it is estimated that 25% of women with breast cancer who have been operated and subjected to standard adjuvant therapies, will have a relapse
Currently the drug is only indicated for prevention of complications of bone metastases, although research points to its ability to prevent relapses in other organs also
Treatment with Zometa ®, zoledronic acid, could prevent recurrence of breast cancer to nearly 800 women in Spain, as concluded by Dr. Michael Martin, president of the Spanish Group for Breast Cancer Research, GEICAM, from data provided by a study recently published in The New England Journal of Medicine. Dr. Martin explained that the treatment was tested in premenopausal women with hormone receptor-positive, and in absolute numbers, achieved a reduction of recurrence of 5%. Dr. Martin goes one step further and suggests that if the benefit of Zometa ® should also apply to postmenopausal women with hormone receptor-negative and could reduce the relapse rate by another 5%, which would mean that, a year in Spain, near 800 women could prevent relapse with this treatment, the doctor estimated.
In Spain are diagnosed each year between 17,000 and 20,000 breast cancer cases and 7000 deaths are recorded by this disease. In this context, Dr. Martin said that despite surgery and standard adjuvant therapy such as chemotherapy, hormone therapy or trastuzumab, it is estimated that 25% of women with breast cancer have a relapse in the future.
Hence the importance of this finding. Dr. Ana Lluch, Head of Service of Hematology and Medical Oncology, Hospital Clínico de Valencia, recognizing the great contribution they can make the administration of zoledronic acid for treatment of breast cancer. The rate of death in Spain because of this tumor has been reduced through early diagnosis programs, which can detect tumors at very initial stages and therefore the possibilities for treatment and cure are much higher. New treatments, taxanes, biological therapies such as trastuzumab, treatment with aromatase inhibitors, letrozole, anastrozole, and exemestane have also helped this reduction in relapse rate, says Dr. who is optimistic about future zoledronic acid injections.
So far, Zometa ® is indicated for the prevention of bone encumbrances arising from metastasis. However, the ABCSG-12 study has shown that zoledronic acid not only prevents locoregional recurrence, but systemic recurrence, such as lung or skin, which is what causes death, says Ana Lluch.
The study involved more than 1,800 premenopausal women with breast cancer in initial stage, after being subjected to curative surgery and treatment with goserelin to achieve ovarian suppression with hormonal therapy were treated with or without Zometa ® for three years. After a follow-up period with an average duration of 48 months, results showed that the addition of Zometa ® to hormone therapy (tamoxifen or anastrozole) reduced by 36% the risk of relapse or death.
Dr. Lluch explains that premenopausal women have a higher risk of relapse than postmenopausal women, especially systemic or distant relapse, since age is a pejorative factor. Postmenopausal women constitute 60% of patients with breast cancer in Spain, compared with 40% of premenopausal and therefore welcomes the fact that also other studies being developed for the application of zoledronic acid in postmenopausal women. We are convinced that zoledronic acid will also have a double effect on these women. He had already proven effective in increasing bone density, if confirmed to be effective in preventing relapse of breast cancer, could have an important place in the treatment of postmenopausal women.
For the doctor, who has a drug without significant side effects and also may reduce distant metastases, which help prevent bone loss in patients and decrease the risk of fracture is very important and we are transmitting to patients. Women from 50 to 55 years are concerned about a quality of life that will not have problems associated with bone fracture risk and this is where we can give good news.
Study characteristics
The study ABCSG-12 cooperative group Austrian Austrian Breast & Colorectal Cancer Study Group (ABCSG) is the first large clinical study, Phase III, randomized, reflecting that Zometa ® provides significant protection against recurrence of breast cancer in phase Initial in premenopausal women.
The ABCSG-12 is an open-label, multicentre joined 1803 premenopausal women with breast cancer estrogen receptor positive stage I or II, with involvement of fewer than 10 axillary lymph nodes. The patients were incorporated into the study after being subjected to curative surgery and initiation of treatment with goserelin for ovarian suppression, being randomly assigned to one of four study groups: (1) anastrozole over zoledronic acid, (2) anastrozole separately , (3) tamoxifen plus zoledronic acid, (4) tamoxifen alone. The treatment period was three years and the average follow up period was 48 months at the current analysis.
The primary endpoint of the four groups of study was disease-free survival or systemic recurrence. The locoregional recurrence-free survival, overall survival and bone mineral density were secondary endpoints.
With a mean follow up of 48 months, developments in disease-free survival or systemic recurrence was reduced by 36% (P = 0.01) and the risk of local recurrence-free events dropped by 35% (P = 0.02) Zometa ® added to hormone therapy compared with hormonal therapy alone. There were 16 deaths among patients who received Zometa ® with hormonal therapy, compared with 26 patients receiving hormonal sóloterapia, which entailed a nonsignificant reduction in risk of death in patients receiving Zometa ® compared with those received hormonal therapy alone (P = 0.11). A similar trend was observed in the reduction of bone metastases among patients receiving Zometa ® compared with those who received hormone therapy alone (P = 0.22). You will need longer follow-up and a larger number of events to determine if there are significant differences between groups in overall survival and survival free of bone metastasis. In general, treatment was well tolerated and side effects were consistent with the known safety profile of medicamento1.
About Zometa ®
Zometa ®, zoledronic acid, is indicated for the prevention of skeletal related events (pathological fractures, spinal cord compression, radiation or surgery to bone) in patients with advanced malignancies involving bone, and for the treatment of hypercalcemia induced by tumor. Zometa ® is approved and indicated for the treatment of patients with advanced tumors involving bone. Zometa ® is approved and indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases in solid tumors, along with the usual antineoplastic therapy. Zometa ®, an intravenous bisphosphonate, is the only treatment able to show efficacy in reducing or delaying bone complications in various types of tumors such as breast, prostate, lung and renal cell cancer, administering monthly in patients with metastatic disease. Zometa ® provides patients, health professionals and medical practice 15 minutes infusion.
Zometa ® is the leading treatment worldwide for the prevention or delay of skeletal related events (SREs) in patients with advanced tumors with bone involvement in a wide variety of tumors. The laboratory research has suggested that zoledronic acid could also help to protect patients in the spread of cancer to other parts of the body (distant metastases areas) and help keep patients recurrence-free, although not approved indication for Zometa ®.
Zometa ® slows the bone-destroying effect that occurs with bone metastases, combating abnormal activation of osteoclasts, cells that normally deteriorate old bone, and osteoblasts, cells that normally participate in the development of new bone. Growth factors produced by cancer cells on osteoclasts and stimulate osteoblasts, causing excessive erosion of bone and / or the accumulation of new bone, but unstable.
Important Safety Information
In clinical studies, the safety profile with Zometa ® was similar to that of pamidronate. Zometa ® has been associated with reports of kidney failure. Patients should be monitored serum creatinine level before receiving each dose of Zometa. Caution is advised when Zometa ® use in patients sensitive to aspirin or with aminoglycosides, loop diuretics, and other potentially nephrotoxic drugs. Due to the risk of clinically significant deterioration in renal function, single doses of Zometa ® should not exceed 4 mg. and duration of infusion should not be less than 15 minutes in 100ml. diluent.
In clinical studies in patients with bone metastases and hypercalcemia of malignancy, Zometa ® had a safety profile similar to other oral bisphosphonates. The most frequently reported adverse events were flu-like syndrome (fever, arthralgias, myalgias, skeletal pain), fatigue, gastrointestinal reactions, anemia, weakness, cough, dyspnea and edema. Zometa ® should not be used during pregnancy. Zometa ® is contraindicated in patients with clinically significant hypersensitivity to zoledronic acid or other bisphosphonates, or any of the excipients in the formulation of Zometa ®.
Osteonecrosis of the jaw (ONJ): ONJ has been reported of patients with cancer receiving treatment including bisphosphonates, chemotherapy and / or corticosteroids. Most reported cases have been associated with dental procedures like dental extractions. It should consider a dental examination with appropriate preventive dental care before treatment with bisphosphonates in patients with concomitant risk factors. During treatment, these patients should avoid invasive dental procedures whenever possible. We have no data to suggest whether the cessation of bisphosphonate therapy reduces the risk of ONJ in patients requiring dental procedures.
In Spain it is estimated that 25% of women with breast cancer who have been operated and subjected to standard adjuvant therapies, will have a relapse
Currently the drug is only indicated for prevention of complications of bone metastases, although research points to its ability to prevent relapses in other organs also
Treatment with Zometa ®, zoledronic acid, could prevent recurrence of breast cancer to nearly 800 women in Spain, as concluded by Dr. Michael Martin, president of the Spanish Group for Breast Cancer Research, GEICAM, from data provided by a study recently published in The New England Journal of Medicine. Dr. Martin explained that the treatment was tested in premenopausal women with hormone receptor-positive, and in absolute numbers, achieved a reduction of recurrence of 5%. Dr. Martin goes one step further and suggests that if the benefit of Zometa ® should also apply to postmenopausal women with hormone receptor-negative and could reduce the relapse rate by another 5%, which would mean that, a year in Spain, near 800 women could prevent relapse with this treatment, the doctor estimated.
In Spain are diagnosed each year between 17,000 and 20,000 breast cancer cases and 7000 deaths are recorded by this disease. In this context, Dr. Martin said that despite surgery and standard adjuvant therapy such as chemotherapy, hormone therapy or trastuzumab, it is estimated that 25% of women with breast cancer have a relapse in the future.
Hence the importance of this finding. Dr. Ana Lluch, Head of Service of Hematology and Medical Oncology, Hospital Clínico de Valencia, recognizing the great contribution they can make the administration of zoledronic acid for treatment of breast cancer. The rate of death in Spain because of this tumor has been reduced through early diagnosis programs, which can detect tumors at very initial stages and therefore the possibilities for treatment and cure are much higher. New treatments, taxanes, biological therapies such as trastuzumab, treatment with aromatase inhibitors, letrozole, anastrozole, and exemestane have also helped this reduction in relapse rate, says Dr. who is optimistic about future zoledronic acid injections.
So far, Zometa ® is indicated for the prevention of bone encumbrances arising from metastasis. However, the ABCSG-12 study has shown that zoledronic acid not only prevents locoregional recurrence, but systemic recurrence, such as lung or skin, which is what causes death, says Ana Lluch.
The study involved more than 1,800 premenopausal women with breast cancer in initial stage, after being subjected to curative surgery and treatment with goserelin to achieve ovarian suppression with hormonal therapy were treated with or without Zometa ® for three years. After a follow-up period with an average duration of 48 months, results showed that the addition of Zometa ® to hormone therapy (tamoxifen or anastrozole) reduced by 36% the risk of relapse or death.
Dr. Lluch explains that premenopausal women have a higher risk of relapse than postmenopausal women, especially systemic or distant relapse, since age is a pejorative factor. Postmenopausal women constitute 60% of patients with breast cancer in Spain, compared with 40% of premenopausal and therefore welcomes the fact that also other studies being developed for the application of zoledronic acid in postmenopausal women. We are convinced that zoledronic acid will also have a double effect on these women. He had already proven effective in increasing bone density, if confirmed to be effective in preventing relapse of breast cancer, could have an important place in the treatment of postmenopausal women.
For the doctor, who has a drug without significant side effects and also may reduce distant metastases, which help prevent bone loss in patients and decrease the risk of fracture is very important and we are transmitting to patients. Women from 50 to 55 years are concerned about a quality of life that will not have problems associated with bone fracture risk and this is where we can give good news.
Study characteristics
The study ABCSG-12 cooperative group Austrian Austrian Breast & Colorectal Cancer Study Group (ABCSG) is the first large clinical study, Phase III, randomized, reflecting that Zometa ® provides significant protection against recurrence of breast cancer in phase Initial in premenopausal women.
The ABCSG-12 is an open-label, multicentre joined 1803 premenopausal women with breast cancer estrogen receptor positive stage I or II, with involvement of fewer than 10 axillary lymph nodes. The patients were incorporated into the study after being subjected to curative surgery and initiation of treatment with goserelin for ovarian suppression, being randomly assigned to one of four study groups: (1) anastrozole over zoledronic acid, (2) anastrozole separately , (3) tamoxifen plus zoledronic acid, (4) tamoxifen alone. The treatment period was three years and the average follow up period was 48 months at the current analysis.
The primary endpoint of the four groups of study was disease-free survival or systemic recurrence. The locoregional recurrence-free survival, overall survival and bone mineral density were secondary endpoints.
With a mean follow up of 48 months, developments in disease-free survival or systemic recurrence was reduced by 36% (P = 0.01) and the risk of local recurrence-free events dropped by 35% (P = 0.02) Zometa ® added to hormone therapy compared with hormonal therapy alone. There were 16 deaths among patients who received Zometa ® with hormonal therapy, compared with 26 patients receiving hormonal sóloterapia, which entailed a nonsignificant reduction in risk of death in patients receiving Zometa ® compared with those received hormonal therapy alone (P = 0.11). A similar trend was observed in the reduction of bone metastases among patients receiving Zometa ® compared with those who received hormone therapy alone (P = 0.22). You will need longer follow-up and a larger number of events to determine if there are significant differences between groups in overall survival and survival free of bone metastasis. In general, treatment was well tolerated and side effects were consistent with the known safety profile of medicamento1.
About Zometa ®
Zometa ®, zoledronic acid, is indicated for the prevention of skeletal related events (pathological fractures, spinal cord compression, radiation or surgery to bone) in patients with advanced malignancies involving bone, and for the treatment of hypercalcemia induced by tumor. Zometa ® is approved and indicated for the treatment of patients with advanced tumors involving bone. Zometa ® is approved and indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases in solid tumors, along with the usual antineoplastic therapy. Zometa ®, an intravenous bisphosphonate, is the only treatment able to show efficacy in reducing or delaying bone complications in various types of tumors such as breast, prostate, lung and renal cell cancer, administering monthly in patients with metastatic disease. Zometa ® provides patients, health professionals and medical practice 15 minutes infusion.
Zometa ® is the leading treatment worldwide for the prevention or delay of skeletal related events (SREs) in patients with advanced tumors with bone involvement in a wide variety of tumors. The laboratory research has suggested that zoledronic acid could also help to protect patients in the spread of cancer to other parts of the body (distant metastases areas) and help keep patients recurrence-free, although not approved indication for Zometa ®.
Zometa ® slows the bone-destroying effect that occurs with bone metastases, combating abnormal activation of osteoclasts, cells that normally deteriorate old bone, and osteoblasts, cells that normally participate in the development of new bone. Growth factors produced by cancer cells on osteoclasts and stimulate osteoblasts, causing excessive erosion of bone and / or the accumulation of new bone, but unstable.
Important Safety Information
In clinical studies, the safety profile with Zometa ® was similar to that of pamidronate. Zometa ® has been associated with reports of kidney failure. Patients should be monitored serum creatinine level before receiving each dose of Zometa. Caution is advised when Zometa ® use in patients sensitive to aspirin or with aminoglycosides, loop diuretics, and other potentially nephrotoxic drugs. Due to the risk of clinically significant deterioration in renal function, single doses of Zometa ® should not exceed 4 mg. and duration of infusion should not be less than 15 minutes in 100ml. diluent.
In clinical studies in patients with bone metastases and hypercalcemia of malignancy, Zometa ® had a safety profile similar to other oral bisphosphonates. The most frequently reported adverse events were flu-like syndrome (fever, arthralgias, myalgias, skeletal pain), fatigue, gastrointestinal reactions, anemia, weakness, cough, dyspnea and edema. Zometa ® should not be used during pregnancy. Zometa ® is contraindicated in patients with clinically significant hypersensitivity to zoledronic acid or other bisphosphonates, or any of the excipients in the formulation of Zometa ®.
Osteonecrosis of the jaw (ONJ): ONJ has been reported of patients with cancer receiving treatment including bisphosphonates, chemotherapy and / or corticosteroids. Most reported cases have been associated with dental procedures like dental extractions. It should consider a dental examination with appropriate preventive dental care before treatment with bisphosphonates in patients with concomitant risk factors. During treatment, these patients should avoid invasive dental procedures whenever possible. We have no data to suggest whether the cessation of bisphosphonate therapy reduces the risk of ONJ in patients requiring dental procedures.
Alcohol and cigarettes cause cancer cases is increasing in the UK
Alcohol and cigarettes cause cancer cases is increasing in the UK
A study conducted by the UK Cancer Research Foundation of alcohol use in the country doubled since 1950, was revealed.
Alcohol use in terms of human health risks associated with large pointed out that the Cancer Research Foundation, the alcohol because the lips, mouth, tongue and throat cancer at a rate of 26 percent increase in the number caught was emphasized. The report also ride in the UK every year 800 people died from cancer because of the alcohol was attention. Alcohol also causes cancer of the cervix in the report as an important influence, "Oral cancer, 75 percent caught smoking and drinking alcohol comes from." was said. Evaluate the results of the Professor. Dr. Ian Gilmore, "These results showed that substances such as alcohol and cigarettes are not only older people are at risk for people of all ages." said.
A study conducted by the UK Cancer Research Foundation of alcohol use in the country doubled since 1950, was revealed.
Alcohol use in terms of human health risks associated with large pointed out that the Cancer Research Foundation, the alcohol because the lips, mouth, tongue and throat cancer at a rate of 26 percent increase in the number caught was emphasized. The report also ride in the UK every year 800 people died from cancer because of the alcohol was attention. Alcohol also causes cancer of the cervix in the report as an important influence, "Oral cancer, 75 percent caught smoking and drinking alcohol comes from." was said. Evaluate the results of the Professor. Dr. Ian Gilmore, "These results showed that substances such as alcohol and cigarettes are not only older people are at risk for people of all ages." said.
Sunday, February 15, 2009
The economic crisis comes to homes and reduce their levels of occupancy.
Occupancy has fallen by 10% in the last five years.
- Average occupancy in the area of larger homes has fallen almost 5% between 2007 and 2006.
- The number of workers in residential growth is greater than the number of users.
- Euskoges faces the crisis by implementing management systems, quality and investment.
- "At the moment we must promote the values and services of the residence by management systems to cope with the situation," says Gabirel of Azaola manager Euskoges.
The factors are varied, but the residential sector for older people is being affected by the current economic crisis. Official data indicate a decrease in average occupancy at these sites up to 10% in the last five years. In fact, between 2007 and 2006 the average occupancy in residential and day care centers in Bizkaia fell almost 5%.
Asked about the issue of Gabirel Azaola, manager of Euskoges Group, says that the causes that have led to this situation are diverse. "We must take into account the increased offer. The number of places offered has grown over the number of seats occupied. " However, Euskoges-group they belong to the residential neighborhood and the residence Barrika Kirikiño Bilbao, has managed to maintain their occupancy levels above the industry average "through differentiation in service quality and investment."
The increase in prices in this area has also been decisive. In this sense, Gabirel Azaola points of change that has occurred in the subsidy schemes of residential places, a factor that was a slowdown in the number of requests for such places. The previous system gave support sunk after completing requirements. Now, the public is the owner of the square and provides the service upon request, generating an acknowledgment of debt for which you paid on the basis of available assets. "This led to a fall in applications for aid, especially two years ago, but has been corrected."
Even the new Act Unit assumed "some brake on the number of new users, since many people had been pending for their rights, which could receive aid, and in this sense," the new aid to informal caregivers can delay the entry in residence. "
Investing in times of crisis
Seated against the thought of "tighten their belts" when the economic situation is favorable, from a Euskoges still more focused on the forecast. "It's important to bring forward the investment and be prepared for times of crisis. In this way, the company becomes stronger and can take advantage, or at least cope with the situation in the best possible way, "says Gabirel of Azaola. Group Euskoges already invested $ 150,000 of the 300,000 expected by 2009 to improve facilities and management of their schools.
The work and commitment is reflected Euskoges with several awards: ISO 9001-2000 (Quality) in the care of older people (May 2006), ISO 14000-2004 Environment (May 2006), ISO 9001-2000 Certification the management of food in the schools themselves by Cuisine Cantabrica GASC (September 2007), Diploma Euskalit Foundation for its commitment to total quality management and excellent proven (October 2007).
The number of workers grows over the user
The data on direct care staff have been accounted for 3569 workers in residential Vizcaya, an increase of 15.31% compared to 2006. This increase is remarkable when one considers the number of users has grown by only 5.49%. For professional categories, the group with higher weight in homes, community housing and day care centers is gerocultor - assistant.
According to official figures until December 31, 2007 in Bizkaia there are 142 senior centers that offer a total of 9002 seats. These figures represent an increase over the previous year of 8.40% in number of residences and 7.98% in seats.
Bilbao meets 28% of total residential places (2,558 places), but the county with the highest number of seats is Busturia-specific Uribe with 30% (2,709 seats). In those areas where facilities are located Euskoges: Residence Kirikiño (Bilbao) and the Residence Barrika Barri.
While the total of places in residential Bizkaia increased by 7.98%, the population over 65 years grew by 1.75%. Thus, the degree of coverage of places on this population reaches 4.07% in Bizkaia. Regarding the coverage residential places (including homes, supervised community housing and apartments), the coverage is at 4.60%.
With regard to the rates in this sector, Bizkaia reach more than 2200 euros a month. For its part, the average monthly public cost for dependents at a place agreed to over 2,000 euros last year.
- Average occupancy in the area of larger homes has fallen almost 5% between 2007 and 2006.
- The number of workers in residential growth is greater than the number of users.
- Euskoges faces the crisis by implementing management systems, quality and investment.
- "At the moment we must promote the values and services of the residence by management systems to cope with the situation," says Gabirel of Azaola manager Euskoges.
The factors are varied, but the residential sector for older people is being affected by the current economic crisis. Official data indicate a decrease in average occupancy at these sites up to 10% in the last five years. In fact, between 2007 and 2006 the average occupancy in residential and day care centers in Bizkaia fell almost 5%.
Asked about the issue of Gabirel Azaola, manager of Euskoges Group, says that the causes that have led to this situation are diverse. "We must take into account the increased offer. The number of places offered has grown over the number of seats occupied. " However, Euskoges-group they belong to the residential neighborhood and the residence Barrika Kirikiño Bilbao, has managed to maintain their occupancy levels above the industry average "through differentiation in service quality and investment."
The increase in prices in this area has also been decisive. In this sense, Gabirel Azaola points of change that has occurred in the subsidy schemes of residential places, a factor that was a slowdown in the number of requests for such places. The previous system gave support sunk after completing requirements. Now, the public is the owner of the square and provides the service upon request, generating an acknowledgment of debt for which you paid on the basis of available assets. "This led to a fall in applications for aid, especially two years ago, but has been corrected."
Even the new Act Unit assumed "some brake on the number of new users, since many people had been pending for their rights, which could receive aid, and in this sense," the new aid to informal caregivers can delay the entry in residence. "
Investing in times of crisis
Seated against the thought of "tighten their belts" when the economic situation is favorable, from a Euskoges still more focused on the forecast. "It's important to bring forward the investment and be prepared for times of crisis. In this way, the company becomes stronger and can take advantage, or at least cope with the situation in the best possible way, "says Gabirel of Azaola. Group Euskoges already invested $ 150,000 of the 300,000 expected by 2009 to improve facilities and management of their schools.
The work and commitment is reflected Euskoges with several awards: ISO 9001-2000 (Quality) in the care of older people (May 2006), ISO 14000-2004 Environment (May 2006), ISO 9001-2000 Certification the management of food in the schools themselves by Cuisine Cantabrica GASC (September 2007), Diploma Euskalit Foundation for its commitment to total quality management and excellent proven (October 2007).
The number of workers grows over the user
The data on direct care staff have been accounted for 3569 workers in residential Vizcaya, an increase of 15.31% compared to 2006. This increase is remarkable when one considers the number of users has grown by only 5.49%. For professional categories, the group with higher weight in homes, community housing and day care centers is gerocultor - assistant.
According to official figures until December 31, 2007 in Bizkaia there are 142 senior centers that offer a total of 9002 seats. These figures represent an increase over the previous year of 8.40% in number of residences and 7.98% in seats.
Bilbao meets 28% of total residential places (2,558 places), but the county with the highest number of seats is Busturia-specific Uribe with 30% (2,709 seats). In those areas where facilities are located Euskoges: Residence Kirikiño (Bilbao) and the Residence Barrika Barri.
While the total of places in residential Bizkaia increased by 7.98%, the population over 65 years grew by 1.75%. Thus, the degree of coverage of places on this population reaches 4.07% in Bizkaia. Regarding the coverage residential places (including homes, supervised community housing and apartments), the coverage is at 4.60%.
With regard to the rates in this sector, Bizkaia reach more than 2200 euros a month. For its part, the average monthly public cost for dependents at a place agreed to over 2,000 euros last year.
Animal studies show that oil consumption slows growth of cancer.
- Research shows that the tumors before and come out are bigger and there are more animals in the affected animals taking large amounts of corn oil, unlike the animals that have taken olive oil whose tumors are benign.
- The conclusions of this work, developed by a research group at the Autonomous University of Barcelona (UAB), which coordinates the teacher Eduard Escriche, will be exhibited at the Second International Conference on Olive Oil and Health to be held in Cordoba and Jaen 20 to November 22.
The scientific evidence has shown that in vivo studies developed by the Multidisciplinary Group for the Study of Breast Cancer at UAB indicate that corn oil is a fat harmful if consumed in excess, while the oil is beneficial if drink moderately, as the coordinator of the group progresses, Eduard Escriche. The UAB team conducts its research work with a model of experimental breast cancer by studying the effects on animal consumption of two types of fats: corn oil and olive. The studies cover three approaches: the clinician, the morphological, and finally, the study of molecular mechanisms. Some investigations have revealed that the protective effect of olive oil against cancer.
"We conducted 16 experimental series and the seed oil always true. For animals who are taking large amounts of corn oil tumors before they leave, there are more animals with breast cancer, there are more number of tumors per animal, and the tumors are larger. Ie carcinogenesis is important in animals that take over corn oil, "explains Professor of Cell Biology, Physiology and Immunology. However, Escriche stresses that corn oil did not cause cancer but acts more on the promotion of this cancer, accelerating the clinical course of the disease.
What about olive oil? "Clinically, it is very clear its salutary effect: something is olive oil that despite a large amount supplied counteracts the negative effect it may have, as it is fat," she says. Fat provides energy that is the fuel needed by the tumor or cancerous cell that is why, in principle, any fat can be harmful, says the researcher. "But something is olive oil that counteracts this possible adverse effect: the specific mechanisms that we analyze the morphological and molecular studies.
Indeed, experimental studies morphological, ie, those discussed in the microscopic appearance of tumor, have revealed that the tumors originated in animals that have taken olive oil are more benign, the tumors of animals taken corn oil. A point in favor of olive oil. In addition, the teacher indicated that his research team as the other groups participating in this conference have shown that molecular data exist that support the health benefits of olive oil in relation to cancer.
To date, experiments have shown that never developed olive oil has the capacity to reverse tumor that already exists. "But we can contribute to the fight against cancer because our results indicate that slows the growth of this tumor and disease progression, although we can not classify andalusia olive oil as a drug."
All these research results will be presented at the symposium on olive oil and cancer in the II International Congress on olive oil and health to be held in Jaén and Córdoba 20 to November 22, who will moderate the Escriche, and where will know the results of research of other specialists in this field.
Olive oil for cooking
Regarding eating habits, the researchers noted that currently consume more fat than humans are of animal origin. But on the other hand, the fat oil seeds, is cheaper, is being used much in the kitchen, shifting to other types of oil like olive. " However, olive oil is kept more stable, it holds more heat and less distortion (the changes are problematic for health) to be used in cooking. That is why it is incomprehensible Eduard Escriche the current situation in the kitchens of the public: "It is a public health issue and someone should be made to understand that restaurants should not be used as the types of sunflower oils that can be harmful to health. "
But the protective effect of olive oil against cancer is also present in the crude oil for two reasons: for it contains oleic acid, a fatty acid that is behaving in a healthy manner in their interactions with cells and the components minority's exclusive extra virgin olive oil, such as antioxidants or squalene, very beneficial to many more aspects of health. Therefore, the fact administer on a regular basis could have beneficial effects.
"My recommendation would be moderate dietary consumption of fats in general by reducing animal fats and omega 6 polyunsaturated fats (the latter present in seed oils), and increasing, but within the proper amount, the olive oil and the omega 3 in fish oils and blue. Consumers should take the olive oil from an early age and acquire a healthy diet but in moderation, "advises the scientist.
- The conclusions of this work, developed by a research group at the Autonomous University of Barcelona (UAB), which coordinates the teacher Eduard Escriche, will be exhibited at the Second International Conference on Olive Oil and Health to be held in Cordoba and Jaen 20 to November 22.
The scientific evidence has shown that in vivo studies developed by the Multidisciplinary Group for the Study of Breast Cancer at UAB indicate that corn oil is a fat harmful if consumed in excess, while the oil is beneficial if drink moderately, as the coordinator of the group progresses, Eduard Escriche. The UAB team conducts its research work with a model of experimental breast cancer by studying the effects on animal consumption of two types of fats: corn oil and olive. The studies cover three approaches: the clinician, the morphological, and finally, the study of molecular mechanisms. Some investigations have revealed that the protective effect of olive oil against cancer.
"We conducted 16 experimental series and the seed oil always true. For animals who are taking large amounts of corn oil tumors before they leave, there are more animals with breast cancer, there are more number of tumors per animal, and the tumors are larger. Ie carcinogenesis is important in animals that take over corn oil, "explains Professor of Cell Biology, Physiology and Immunology. However, Escriche stresses that corn oil did not cause cancer but acts more on the promotion of this cancer, accelerating the clinical course of the disease.
What about olive oil? "Clinically, it is very clear its salutary effect: something is olive oil that despite a large amount supplied counteracts the negative effect it may have, as it is fat," she says. Fat provides energy that is the fuel needed by the tumor or cancerous cell that is why, in principle, any fat can be harmful, says the researcher. "But something is olive oil that counteracts this possible adverse effect: the specific mechanisms that we analyze the morphological and molecular studies.
Indeed, experimental studies morphological, ie, those discussed in the microscopic appearance of tumor, have revealed that the tumors originated in animals that have taken olive oil are more benign, the tumors of animals taken corn oil. A point in favor of olive oil. In addition, the teacher indicated that his research team as the other groups participating in this conference have shown that molecular data exist that support the health benefits of olive oil in relation to cancer.
To date, experiments have shown that never developed olive oil has the capacity to reverse tumor that already exists. "But we can contribute to the fight against cancer because our results indicate that slows the growth of this tumor and disease progression, although we can not classify andalusia olive oil as a drug."
All these research results will be presented at the symposium on olive oil and cancer in the II International Congress on olive oil and health to be held in Jaén and Córdoba 20 to November 22, who will moderate the Escriche, and where will know the results of research of other specialists in this field.
Olive oil for cooking
Regarding eating habits, the researchers noted that currently consume more fat than humans are of animal origin. But on the other hand, the fat oil seeds, is cheaper, is being used much in the kitchen, shifting to other types of oil like olive. " However, olive oil is kept more stable, it holds more heat and less distortion (the changes are problematic for health) to be used in cooking. That is why it is incomprehensible Eduard Escriche the current situation in the kitchens of the public: "It is a public health issue and someone should be made to understand that restaurants should not be used as the types of sunflower oils that can be harmful to health. "
But the protective effect of olive oil against cancer is also present in the crude oil for two reasons: for it contains oleic acid, a fatty acid that is behaving in a healthy manner in their interactions with cells and the components minority's exclusive extra virgin olive oil, such as antioxidants or squalene, very beneficial to many more aspects of health. Therefore, the fact administer on a regular basis could have beneficial effects.
"My recommendation would be moderate dietary consumption of fats in general by reducing animal fats and omega 6 polyunsaturated fats (the latter present in seed oils), and increasing, but within the proper amount, the olive oil and the omega 3 in fish oils and blue. Consumers should take the olive oil from an early age and acquire a healthy diet but in moderation, "advises the scientist.
Saturday, February 14, 2009
Tuberculosis and pneumonia are some key indicators of AIDS.
● The pneumologists recommend HIV testing to patients presenting with suspected diagnosis of pulmonary infections.
Given the importance of early diagnosis of HIV infection specialists SEPAR (Spanish Society of Pneumology and Thoracic Surgery) recommend the test to detect this disease prior consent to patients presenting with suspected diagnosis of tuberculosis or pneumonia of certain . Both diseases involve the diagnosis of AIDS as experienced by HIV-infected patients.
Dr. Julio Ancochea, SEPAR president, believes that "practitioners of respiratory diseases are involved in the fight against AIDS through its early warning through involving tuberculosis and pneumonia in certain possible HIV . In Spain, are currently between 120,000 and 150,000 people infected with HIV and an estimated 25% of underdiagnosing, ie ignoring patients infected with the virus. This consideration assumes great significance as a factor that increases the risk of infection.
The figures corroborate the close realción between AIDS and respiratory infections. Over 50% of AIDS-indicative diseases affecting the lungs. In Spain, according to data from the National Registry of AIDS in 2003-2007 was 8786 cases, of which 29.2% were tuberculosis, 22.7% for Pneumocystis jirovecii pneumonia (formerly Pneumocystis carinii), and 6.5% for bacterial pneumonia recurrence.
Dr. Joan Cayla, an epidemiologist and member of SEPAR provides the following figures: "In Barcelona, the 3931 cases detected from January 1994 to September 30, 2008, 32.1% were atuberculosis, 20.3% Pneumocystis jirovecii pneumonia, bacterial pneumonia 2.6% repeatability, 1.2% other mycobacterial pulmonary infections, 0.2 to bronchial or pulmonary candidiasis, 0.1% to lymphoid interstitial pneumonia, 0 , herpes simplex 1% to 0.1% and bronquial to disseminated histoplasmosis. Dr. Cayla considered, as other experts from different scientific disciplines, that "although each time there is more progress to combat the disease, the best weapon is prevention and early detection."
Recommending HIV testing to detect a respiratory illnesses mentioned, is especially relevant when further matches the high prevalence of tuberculosis in the immigrant group from certain geographic areas, a group of people who in 2007 led 20.7% of people suffering from AIDS in Spain, according to data from the National AIDS Plan. This intimate relationship between tuberculosis and AIDS reaches its maximum effect to the expectations of an increase in this figure in the coming years as 34% of newly infected HIV belongs to this group. According to official data, in 2007 there were 1345 new cases of AIDS, of whom 19.3% are immigrants.
Given the importance of early diagnosis of HIV infection specialists SEPAR (Spanish Society of Pneumology and Thoracic Surgery) recommend the test to detect this disease prior consent to patients presenting with suspected diagnosis of tuberculosis or pneumonia of certain . Both diseases involve the diagnosis of AIDS as experienced by HIV-infected patients.
Dr. Julio Ancochea, SEPAR president, believes that "practitioners of respiratory diseases are involved in the fight against AIDS through its early warning through involving tuberculosis and pneumonia in certain possible HIV . In Spain, are currently between 120,000 and 150,000 people infected with HIV and an estimated 25% of underdiagnosing, ie ignoring patients infected with the virus. This consideration assumes great significance as a factor that increases the risk of infection.
The figures corroborate the close realción between AIDS and respiratory infections. Over 50% of AIDS-indicative diseases affecting the lungs. In Spain, according to data from the National Registry of AIDS in 2003-2007 was 8786 cases, of which 29.2% were tuberculosis, 22.7% for Pneumocystis jirovecii pneumonia (formerly Pneumocystis carinii), and 6.5% for bacterial pneumonia recurrence.
Dr. Joan Cayla, an epidemiologist and member of SEPAR provides the following figures: "In Barcelona, the 3931 cases detected from January 1994 to September 30, 2008, 32.1% were atuberculosis, 20.3% Pneumocystis jirovecii pneumonia, bacterial pneumonia 2.6% repeatability, 1.2% other mycobacterial pulmonary infections, 0.2 to bronchial or pulmonary candidiasis, 0.1% to lymphoid interstitial pneumonia, 0 , herpes simplex 1% to 0.1% and bronquial to disseminated histoplasmosis. Dr. Cayla considered, as other experts from different scientific disciplines, that "although each time there is more progress to combat the disease, the best weapon is prevention and early detection."
Recommending HIV testing to detect a respiratory illnesses mentioned, is especially relevant when further matches the high prevalence of tuberculosis in the immigrant group from certain geographic areas, a group of people who in 2007 led 20.7% of people suffering from AIDS in Spain, according to data from the National AIDS Plan. This intimate relationship between tuberculosis and AIDS reaches its maximum effect to the expectations of an increase in this figure in the coming years as 34% of newly infected HIV belongs to this group. According to official data, in 2007 there were 1345 new cases of AIDS, of whom 19.3% are immigrants.
Spanish urologists continue European recommendations for diagnosis and treatment of benign prostatic hyperplasia.
• According to survey, with 388 urologists from all regions, both at the hospital as an outpatient, and public and private.
• Spain is an international reference in Urology, for their high scientific level and action in daily clinical practice.
• The firm has received the second prize for Best Oral Communication in the X International Congress of the Iberoamerican Society of Urogynecology and Neurourología (SINUG).
Spanish urologists showed almost unanimous agreement with the recommendations established for their specialty throughout Europe regarding the diagnosis and treatment of benign prostatic hyperplasia (BPH). So reveals a study that involved 388 urologists from all over Spain, and has received the second prize for best Poster / Oral Communication at the X International Congress of the Iberoamerican Society of Urogynecology and Neurourología (SINUG) held in Portugal last October.
The objective of this research, says Dr. Andres de Palacio, principal investigator of the study and clinical chief of the Urology Department of the Hospital San Rafael de Madrid, was "to assess the diagnosis and treatment performed by urologists Spanish patients with BPH in their daily practice "and" measure the degree of agreement with the recommendations on the management of these patients, which were made in 2006 by the European Association of Urology (EAU-short).
For the study, which has enjoyed the patronage of Astellas Pharma and entitled "Therapeutic and diagnostic approach in routine clinical practice for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS / BPH) Queries Urology "We surveyed 388 urologists from all regions, both at the hospital as an outpatient, and public and private.
Among the findings, highlights the fact that most specialists followed the recommendations of the UAE, which allows professionals to "unify" and "constantly updated on the various pathologies, to give the patient the best approaches diagnosis and therapy, both pharmacological and surgical, such as laser, "specifies Andrés Palacio.
The doctor says, well, that Spain has been "referring to the European and global urology with a high-level scientific and action in daily clinical practice, not only in the HBP, but in all the pathologies covering the specialty. " This is demonstrated by the Spanish participation in the expert committee that drafted the recommendations in 2006.
Pharmacological treatment of BPH
Regarding the drug most frequently chosen by urologists as a first option, the study shows that monotherapy, one in 55.2% of the cases, the drug combination in 19.4% of the time. "The single is the use of herbal medicine alone, alpha-blockers or inhibitors of 5 alpha-reductase, whereas the combination therapy, involves the administration of an alpha-blocker and an inhibitor of 5 alpha-reductase," explains Dr. Palacio.
Within combination therapy, the research reveals that 77.3% of physicians recognized the combination of alpha-blockers and inhibitors of 5 alpha-reductase as the most common. Dr. Andres de Palacio argues that this election is that "it is very beneficial for patients because they receive prompt and sustained resolution of symptoms caused by alpha-blockers and long-term benefits of treatment with inhibitors of 5 alpha-reductase.
Likewise, a 97.2% of physicians considered the study of alpha-blockers as an effective therapy for BPH, "because it produces a more rapid improvement of symptoms and urinary flow rate." Among the alpha-blockers, Dr. de Palacio stressed the effectiveness of tamsulosin, a drug of last generation and is characterized by a very rapid and sustained relief in time of prostatic symptoms. For the specialist, now is the one with less incidence of cardiovascular side effects. "
Finally, in relation to diagnostic procedures, between 96% and 100% of urologists surveyed agreed that the most frequent are the history, physical examination, determination of prostate specific antigen (PSA) and touch rectum. At the other extreme, only 36% said their agreement with the recommendation of using voiding diary, a document completed by the patient which contains the number of voids and volume of urine at each micturition.
• Spain is an international reference in Urology, for their high scientific level and action in daily clinical practice.
• The firm has received the second prize for Best Oral Communication in the X International Congress of the Iberoamerican Society of Urogynecology and Neurourología (SINUG).
Spanish urologists showed almost unanimous agreement with the recommendations established for their specialty throughout Europe regarding the diagnosis and treatment of benign prostatic hyperplasia (BPH). So reveals a study that involved 388 urologists from all over Spain, and has received the second prize for best Poster / Oral Communication at the X International Congress of the Iberoamerican Society of Urogynecology and Neurourología (SINUG) held in Portugal last October.
The objective of this research, says Dr. Andres de Palacio, principal investigator of the study and clinical chief of the Urology Department of the Hospital San Rafael de Madrid, was "to assess the diagnosis and treatment performed by urologists Spanish patients with BPH in their daily practice "and" measure the degree of agreement with the recommendations on the management of these patients, which were made in 2006 by the European Association of Urology (EAU-short).
For the study, which has enjoyed the patronage of Astellas Pharma and entitled "Therapeutic and diagnostic approach in routine clinical practice for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS / BPH) Queries Urology "We surveyed 388 urologists from all regions, both at the hospital as an outpatient, and public and private.
Among the findings, highlights the fact that most specialists followed the recommendations of the UAE, which allows professionals to "unify" and "constantly updated on the various pathologies, to give the patient the best approaches diagnosis and therapy, both pharmacological and surgical, such as laser, "specifies Andrés Palacio.
The doctor says, well, that Spain has been "referring to the European and global urology with a high-level scientific and action in daily clinical practice, not only in the HBP, but in all the pathologies covering the specialty. " This is demonstrated by the Spanish participation in the expert committee that drafted the recommendations in 2006.
Pharmacological treatment of BPH
Regarding the drug most frequently chosen by urologists as a first option, the study shows that monotherapy, one in 55.2% of the cases, the drug combination in 19.4% of the time. "The single is the use of herbal medicine alone, alpha-blockers or inhibitors of 5 alpha-reductase, whereas the combination therapy, involves the administration of an alpha-blocker and an inhibitor of 5 alpha-reductase," explains Dr. Palacio.
Within combination therapy, the research reveals that 77.3% of physicians recognized the combination of alpha-blockers and inhibitors of 5 alpha-reductase as the most common. Dr. Andres de Palacio argues that this election is that "it is very beneficial for patients because they receive prompt and sustained resolution of symptoms caused by alpha-blockers and long-term benefits of treatment with inhibitors of 5 alpha-reductase.
Likewise, a 97.2% of physicians considered the study of alpha-blockers as an effective therapy for BPH, "because it produces a more rapid improvement of symptoms and urinary flow rate." Among the alpha-blockers, Dr. de Palacio stressed the effectiveness of tamsulosin, a drug of last generation and is characterized by a very rapid and sustained relief in time of prostatic symptoms. For the specialist, now is the one with less incidence of cardiovascular side effects. "
Finally, in relation to diagnostic procedures, between 96% and 100% of urologists surveyed agreed that the most frequent are the history, physical examination, determination of prostate specific antigen (PSA) and touch rectum. At the other extreme, only 36% said their agreement with the recommendation of using voiding diary, a document completed by the patient which contains the number of voids and volume of urine at each micturition.
Minimally invasive surgery: Olympus enters into an exclusive agreement with Advanced Surgical Concepts.
- Minimally invasive surgery: Olympus improved credentials for entry into an exclusive sales and distribution with the market leader and technology Advanced Surgical Concepts
Olympus has strengthened its position as a leader in the field of minimally invasive surgery by signing an exclusive agreement to distribute and immediate products of the Irish company Advanced Surgical Concepts worldwide. ASC is the only global provider of operational techniques for laparoscopic ports leading through a single access point - the patient's navel. Olympus is now the exclusive distributor for the full range of products involved.
The single-site surgery laparoendoscópica (surgery LESS) - endoscopic surgery through the navel - is ranked as one of the most important recent innovations in medical technology. As a distributor of TriPorts and QuadPorts developed by ASC, Olympus is now a key player in the technology of this high potential market. Using these ports can be made three or four instruments in the patient's abdomen through a single access point (eg. The navel). So far, the most minimally invasive requiring three or four independent access points.
"As world market leader in the field of endoscopic quality systems, we can now supply ports, optical instruments and manuals for the dynamic field of minimally invasive surgery from a single source," said Heinz Jacqui, Managing Director of Olympus Winter & Ibe, referring to the strategic partnership. In addition to its responsibility in the area of cooperation of sales, this company also operates a subsidiary center development and production of surgical Olympus.
"With the cooperation with Olympus and its global distribution network we can offer our products in combination with the best current endoscopic system," said Frank Bonadies, CEO of Advanced Surgical Concepts Limited. "The synergy between the products of our companies will enable us to dominate the market for LESS surgery and results in long-term cooperation of our companies."
The market for minimally invasive products is constantly expanding. In Europe alone, there are around 900,000 gallbladder operations a year. In the coming years, a greater number of operations of the gallbladder through the umbilicus. Experts predict a significant increase in transactions, including transactions involving a full-surgery without scars within the next few years.
Besides the advantages for the patient in terms of aesthetics and reducing the pain of the healing process, this new form of access to hospital benefits, with costs at the same level as the conventional operational techniques, while the trend towards times shorter hospitalization and lower hospital costs by reducing the risk of post-operative infection.
With its products and systems solutions, Olympus is positioning as a capable partner for the medical sector. Rigid and flexible endoscopes are playing a decisive role in the diagnosis and minimally invasive therapies. The range of company products includes endoscopes and systems solutions for a wide range of internal medicine and surgery, endoscopic video systems, reprocessing systems and a wide selection of products endoterapia.
Olympus has strengthened its position as a leader in the field of minimally invasive surgery by signing an exclusive agreement to distribute and immediate products of the Irish company Advanced Surgical Concepts worldwide. ASC is the only global provider of operational techniques for laparoscopic ports leading through a single access point - the patient's navel. Olympus is now the exclusive distributor for the full range of products involved.
The single-site surgery laparoendoscópica (surgery LESS) - endoscopic surgery through the navel - is ranked as one of the most important recent innovations in medical technology. As a distributor of TriPorts and QuadPorts developed by ASC, Olympus is now a key player in the technology of this high potential market. Using these ports can be made three or four instruments in the patient's abdomen through a single access point (eg. The navel). So far, the most minimally invasive requiring three or four independent access points.
"As world market leader in the field of endoscopic quality systems, we can now supply ports, optical instruments and manuals for the dynamic field of minimally invasive surgery from a single source," said Heinz Jacqui, Managing Director of Olympus Winter & Ibe, referring to the strategic partnership. In addition to its responsibility in the area of cooperation of sales, this company also operates a subsidiary center development and production of surgical Olympus.
"With the cooperation with Olympus and its global distribution network we can offer our products in combination with the best current endoscopic system," said Frank Bonadies, CEO of Advanced Surgical Concepts Limited. "The synergy between the products of our companies will enable us to dominate the market for LESS surgery and results in long-term cooperation of our companies."
The market for minimally invasive products is constantly expanding. In Europe alone, there are around 900,000 gallbladder operations a year. In the coming years, a greater number of operations of the gallbladder through the umbilicus. Experts predict a significant increase in transactions, including transactions involving a full-surgery without scars within the next few years.
Besides the advantages for the patient in terms of aesthetics and reducing the pain of the healing process, this new form of access to hospital benefits, with costs at the same level as the conventional operational techniques, while the trend towards times shorter hospitalization and lower hospital costs by reducing the risk of post-operative infection.
With its products and systems solutions, Olympus is positioning as a capable partner for the medical sector. Rigid and flexible endoscopes are playing a decisive role in the diagnosis and minimally invasive therapies. The range of company products includes endoscopes and systems solutions for a wide range of internal medicine and surgery, endoscopic video systems, reprocessing systems and a wide selection of products endoterapia.
Vissum performed for the first time in Spain, an alternative to corneal transplantation.
- With this new technique, the recovery can be reduced from one year to one week
- It applies to 50% of patients who currently require a traditional cornea transplant
Medical teams and Dr. Gerrit Melles Vissum Ophthalmologic Corporation, led by Dr. Jorge Alió, have, this morning, three endothelial transplant surgery with an innovative technique in the world. The interventions have been conducted at the invitation of Vissum, Dr. Gerrit Melles, corneal surgeon and director of the Netherlands Institute for Innovative Ocular Surgery, Rotterdam, the creator of this procedure and the eye bank of the technology necessary to perform this operation.
Dr Alió Dr Melles-right-left-for-intervention
This surgical technique, called Endothelial keratoplasty of the Descemet membrane (DMEK for short), is the transplantation of the endothelial membrane, which represents a revolution in these operations because it is not complete cornea transplant or his back, as at present.
Approximately half of corneal transplants are currently performed on patients who have suffered an endothelial failure, mainly due to a previous operation that, by its complications, has led to its destruction, either by trauma or endothelial dystrophy . Ultimately, this technique is applicable to half the cases of corneal transplantation, thus avoiding a much longer post, and getting the patient to have a better view. Plus, everything is done in a much more controlled environment, with a more secure technique.
Cornea with slider
In this sense, the post is fast, the patient after surgery, remains in the clinic two hours and then has to keep one or two days to rest in his home. It then conducts a review to verify that the transplanted layer was seated correctly.
According to Prof. Jorge Alió, Vissum medical director, "the difference is important because, until now, we are dealing with disease, although only the diseased endothelial layer, is the transplanting corneal tissue healthy. That means that transplants are a greater amount of tissue that interferes with the passage of light, recovering a little vision. "
However, with the technical DMEK was transplanted the single layer of tissue that is sick, so the surgery is more functional as there is no residual stromal tissue. The consequence is important: the patient recovers much more quickly and completely. Thus, a corneal transplant has a normal rehabilitation period for a year, while this technique is limited to rehabilitation for a week or two at most, "says Prof. Alió.
Another advantage worth noting is that the eyes cornea donors remain full, so that it can be used on another patient. Moreover, in the case of a rejection, which occurs in 18% of cases, the only thing replaced is the tissue where the endothelium. It is, says Dr. Jorge Alió, "a revolution because it can be transplanted for the first time the endothelial layer, which is a single-cell layer of cells that do not play along with the support they have is called basal membrane or Descemet membrane.
This is not an operation that requires a high-tech, but it requires a sophisticated technique of cultivation of donor tissue to be properly prepared, which requires it to be sent from the eye bank in Rotterdam.
This is the first time that the intervention with this innovative surgical procedure is performed outside of Holland. "None other than Dr. Melles has been able to develop this technology to take off the Descemet membrane and take it to the recipient eye," says Dr. Alió. The Dutch ophthalmologist and has operated at approximately one hundred patients in his country, but from today will be implemented in Spain through the Corporation Oftalmológica Vissum.
About VISSUM
Ophthalmologic VISSUM Corporation was founded in 2004 as a result of the union of six of the most prestigious in our country ophthalmologic centers. Is composed of the best medical, paramedical and research, with the most advanced technology to treat all of the different ocular pathologies: Pediatric Ophthalmology, Refractive Laser Surgery, cataracts or retinal disorders, among others.
Corporation Ophthalmologic VISSUM Centers is comprised of over 300 professionals, led by Prof. Dr. Jorge L. Alió, Professor of Ophthalmology, University Miguel Hernández. Most of these centers are certified to ISO-9001 and some of them even with the Joint Commission of the United States, such as Ophthalmological Institute of Alicante. Also, involved in numerous research projects in collaboration with the University Miguel Hernández (Elche) and the University of Alcalá (Madrid), among others.
Ophthalmologic VISSUM Corporation currently has more than 35 clinical centers specialized in Ophthalmology, located in eleven provinces, Alicante, Albacete, Murcia, Almeria, Gran Canaria, Madrid, Sevilla, Cádiz, Guadalajara, Segovia and Zaragoza in 2007 and has closed exercise with a turnover of 32.2 billion euros.
- It applies to 50% of patients who currently require a traditional cornea transplant
Medical teams and Dr. Gerrit Melles Vissum Ophthalmologic Corporation, led by Dr. Jorge Alió, have, this morning, three endothelial transplant surgery with an innovative technique in the world. The interventions have been conducted at the invitation of Vissum, Dr. Gerrit Melles, corneal surgeon and director of the Netherlands Institute for Innovative Ocular Surgery, Rotterdam, the creator of this procedure and the eye bank of the technology necessary to perform this operation.
Dr Alió Dr Melles-right-left-for-intervention
This surgical technique, called Endothelial keratoplasty of the Descemet membrane (DMEK for short), is the transplantation of the endothelial membrane, which represents a revolution in these operations because it is not complete cornea transplant or his back, as at present.
Approximately half of corneal transplants are currently performed on patients who have suffered an endothelial failure, mainly due to a previous operation that, by its complications, has led to its destruction, either by trauma or endothelial dystrophy . Ultimately, this technique is applicable to half the cases of corneal transplantation, thus avoiding a much longer post, and getting the patient to have a better view. Plus, everything is done in a much more controlled environment, with a more secure technique.
Cornea with slider
In this sense, the post is fast, the patient after surgery, remains in the clinic two hours and then has to keep one or two days to rest in his home. It then conducts a review to verify that the transplanted layer was seated correctly.
According to Prof. Jorge Alió, Vissum medical director, "the difference is important because, until now, we are dealing with disease, although only the diseased endothelial layer, is the transplanting corneal tissue healthy. That means that transplants are a greater amount of tissue that interferes with the passage of light, recovering a little vision. "
However, with the technical DMEK was transplanted the single layer of tissue that is sick, so the surgery is more functional as there is no residual stromal tissue. The consequence is important: the patient recovers much more quickly and completely. Thus, a corneal transplant has a normal rehabilitation period for a year, while this technique is limited to rehabilitation for a week or two at most, "says Prof. Alió.
Another advantage worth noting is that the eyes cornea donors remain full, so that it can be used on another patient. Moreover, in the case of a rejection, which occurs in 18% of cases, the only thing replaced is the tissue where the endothelium. It is, says Dr. Jorge Alió, "a revolution because it can be transplanted for the first time the endothelial layer, which is a single-cell layer of cells that do not play along with the support they have is called basal membrane or Descemet membrane.
This is not an operation that requires a high-tech, but it requires a sophisticated technique of cultivation of donor tissue to be properly prepared, which requires it to be sent from the eye bank in Rotterdam.
This is the first time that the intervention with this innovative surgical procedure is performed outside of Holland. "None other than Dr. Melles has been able to develop this technology to take off the Descemet membrane and take it to the recipient eye," says Dr. Alió. The Dutch ophthalmologist and has operated at approximately one hundred patients in his country, but from today will be implemented in Spain through the Corporation Oftalmológica Vissum.
About VISSUM
Ophthalmologic VISSUM Corporation was founded in 2004 as a result of the union of six of the most prestigious in our country ophthalmologic centers. Is composed of the best medical, paramedical and research, with the most advanced technology to treat all of the different ocular pathologies: Pediatric Ophthalmology, Refractive Laser Surgery, cataracts or retinal disorders, among others.
Corporation Ophthalmologic VISSUM Centers is comprised of over 300 professionals, led by Prof. Dr. Jorge L. Alió, Professor of Ophthalmology, University Miguel Hernández. Most of these centers are certified to ISO-9001 and some of them even with the Joint Commission of the United States, such as Ophthalmological Institute of Alicante. Also, involved in numerous research projects in collaboration with the University Miguel Hernández (Elche) and the University of Alcalá (Madrid), among others.
Ophthalmologic VISSUM Corporation currently has more than 35 clinical centers specialized in Ophthalmology, located in eleven provinces, Alicante, Albacete, Murcia, Almeria, Gran Canaria, Madrid, Sevilla, Cádiz, Guadalajara, Segovia and Zaragoza in 2007 and has closed exercise with a turnover of 32.2 billion euros.
The Senate supports the project by Cinta Solidary Disability.
- The Senators will get the tape in the chamber several
Next Tuesday December 16, at 1600 hours, coinciding with the start of the plenary session, the senators will receive in his place by the tape Solidary Disability.
Senate President Javier Rojo, Mario Garcia to receive Sánchez, president of the Spanish Confederation of People with Disabilities and Physical Organic (COCEMFE) and Francisco Miguel Alonso Garcia, president of the Center for Special Use GPS, the project promoter. Ribbon Solidarity initiative's main objective is to obtain economic resources to finance projects related to the integration of persons with disabilities.
The Senate has joined the initiative as "Ambassador of solidarity honor" by supporting a project to improve the quality of life for people with disabilities, a group that includes more than 3,500,000 people in Spain. Improving the working conditions of persons with disabilities through enhanced training activities, an increased sensitivity of the business and investment in accessibility improvements.
Ribbon Solidarity on the project involved some of the most important designers of the national scene, who have selflessly contributed to the design of a ribbon or lanyard to your mobile personal stamp. The tape is available in the shops attached to the project and the benefits iran for social integration and employment of persons with disabilities.
COCEMFE, Spanish Confederation of People with Disabilities and Physical Organic, is a non-governmental non-profit was formed in 1980. Its aim is unite, strengthen, train and coordinate the efforts and activities of the organizations working on behalf of people with physical and functional to defend their rights and improve their quality of life.
The body brings together more than 1,500 organizations are divided into autonomous confederations, national and provincial federations, which in turn, bring together the various local associations.
Wednesday, February 11, 2009
Siemens is the Academy's Hospital Management Certificate Program
Hospital Management Training in Turkey Living in a Hospital Environment Certification Program Single Data 5.Dönemi 'ni' s Open. Health sector investments to accelerate the need for specialist health managers to the increased folding. Both public and private hospitals to run efficiently with the understanding of modern management, health management, especially in the cost analysis was also out. Health organizations, clinical practices and administrative decisions besides cost effectiveness under control to get into the search for managers, while training in this area given the number of faculty who remain poor, the private sector to action by the University geçirdi.Bahçeşehir Acibadem Hospital cooperation of the then Anadolu Health Center with Siemens Academy 'Applied ... Siemens Academy Patients and Anatolia carried out jointly by the Health Center "Applied Hospital Management Certificate Program" in Turkey, the hospital management business in the kitchen aims to teach in this area have to close the open hedeflemekte.18 graduated in May 2008 on promoting 4.dönem Siemens Academy & Anatolia Hospital Wellness Center for Applied Management Certificate Program, the health sector who are interested in new investment in health and career in this field who are planning or working in the health sector for those wishing to two major institutions in this matter knowledge, and experience continue to transfer etmekte.78 hour training in Anatolia Siemens Medical Solutions Health Center and next to the experienced team of industry experience in labor history and academic history as katılmakta.Eğitimler educators, management and organization, medical services, nursing services, especially for finance, marketing, human resources, clinical and biomedical engineering, such as 20 separate Under the program is currently in Turkey verilmekte.Bu title, living in a hospital environment, the processes of the participants to observe the hospital, and one certificate program is able to query. In this sense, the health professionals participating in the program the flagship hospital of the theory not only in practice, can also see how you play. The program last week carried a full day tour of the hospital participants with the process required for each process, the resources and the efficient use of resources in place on the last day of may and with the Forum to the application questions about the process of responsible yöneltebilmektedirler.Programın to provide another value-added is different segmentlerdeki among participants from the hospital by creating a network for future career development in the mutual sharing is to create an environment. Siemens Academy "Applied Hospital Management Certificate Program" and the details are as follows: Training Start Date: January 17, 2009, CumartesiEğitim End Date: 01 March 2009, PazarEğitim Runtime: Total 7 weeks of the end, training on Saturday and Sunday only verilmektedir.Ders Runtime: Basic Courses are 72 hours, 6 hours in elective courses and a total of 78 hours programdır.Ders Hours: Saturday and Sunday morning 10:00 - 18:00 arası verilmektedir.Eğitim evening Place: Anadolu Health Center Johns Hopkins Hospital, GebzeUlaşım: Access to the Anatolian Health Center Registration for the specific locations and shielded kullanılmaktadır.Bilgi services: Siemens AkademiTelefon: 0216 517 6362E-Mail: siemensakademi@siemens.com
Linde Gas Co. medikal customer training
Linde Gas, Inc., in December, safe use of medical gases under the heading of education gave Gebze plant medical customers. Company has large participation in education, gas use, security, equipment, valves, installations, home care issues and customer complaints have been processed. Training with a presentation before the short video presentation izletttirilerek Linde, Linde Gas has been informed about.
Participants tour the factory of the Linde Gas had the opportunity to know more then. Training for end customers in the gift packages and certificates were presented. Medical education in the year 2009 of Linde Gas will continue to report.
Laboratory support from Linde Gas
In the meantime, Kocaeli University Faculty of Education Dean Prof. Dr. The laboratory was established under the leadership of Yunus Kishali all the equipment needed is provided by Linde Gas, Microsoft's free license, Axis of Information Technology gave the necessary installation and consulting support. The ceremony began with laboratory services. Laboratory of Applied Corporate Software to the opening ceremony, Director of Information Technology Ogün Linde Gas Özpınar, Istanbul University Rector Professor. Dr. Sezer Komşuoğlu, Faculty of Education Dean Prof. Dr. Kishali Yunus, General Manager of Microsoft Turkey, Mustafa Çağan and Axis Information Technology Assistant General Manager of Atilla Filiz joined. In the ceremony of the university laboratories contributed to the win thanks to the documents returned. Made a speech at the ceremony the Rector of Kocaeli University Prof.. Dr. Sezer Komşuoğlu: "Business A to Z of all functions in a single software is limited by integrating the effective use of resources aimed at the Enterprise Resource Planning (ERP) systems compared to today's business world the basis for the solution of problems is key. Linde Gas, with the support of Microsoft Turkey and Axis Information Technology has earned our university with Kocaeli University Laboratory of ERP as the Faculty of Economics and Administrative Sciences in principle between the right of the sign are proud. Dynamics AX ERP program for students in undergraduate and current practices to meet the possibility of finding work on their careers and will provide great benefits to the future with confidence, we believe will help to look at, "he said.
University will continue the cooperation with
Linde Gas Data Processing Director Ogün Özpınar in the speech: "Linde Gas, each sector workers do not appear to contribute to a visible successes as an organization to support the education of university-industry cooperation to develop the principle of social responsibility required to support activities and to participate, students level since the brand and products with known causes of this type to increase opportunities to the extent that the project supports. At this stage, our position, our organization and this small initiative of the project stakeholders, participants and students to benefit and to support the "diyerek, Linde Gas will continue cooperation with the university said.
Participants tour the factory of the Linde Gas had the opportunity to know more then. Training for end customers in the gift packages and certificates were presented. Medical education in the year 2009 of Linde Gas will continue to report.
Laboratory support from Linde Gas
In the meantime, Kocaeli University Faculty of Education Dean Prof. Dr. The laboratory was established under the leadership of Yunus Kishali all the equipment needed is provided by Linde Gas, Microsoft's free license, Axis of Information Technology gave the necessary installation and consulting support. The ceremony began with laboratory services. Laboratory of Applied Corporate Software to the opening ceremony, Director of Information Technology Ogün Linde Gas Özpınar, Istanbul University Rector Professor. Dr. Sezer Komşuoğlu, Faculty of Education Dean Prof. Dr. Kishali Yunus, General Manager of Microsoft Turkey, Mustafa Çağan and Axis Information Technology Assistant General Manager of Atilla Filiz joined. In the ceremony of the university laboratories contributed to the win thanks to the documents returned. Made a speech at the ceremony the Rector of Kocaeli University Prof.. Dr. Sezer Komşuoğlu: "Business A to Z of all functions in a single software is limited by integrating the effective use of resources aimed at the Enterprise Resource Planning (ERP) systems compared to today's business world the basis for the solution of problems is key. Linde Gas, with the support of Microsoft Turkey and Axis Information Technology has earned our university with Kocaeli University Laboratory of ERP as the Faculty of Economics and Administrative Sciences in principle between the right of the sign are proud. Dynamics AX ERP program for students in undergraduate and current practices to meet the possibility of finding work on their careers and will provide great benefits to the future with confidence, we believe will help to look at, "he said.
University will continue the cooperation with
Linde Gas Data Processing Director Ogün Özpınar in the speech: "Linde Gas, each sector workers do not appear to contribute to a visible successes as an organization to support the education of university-industry cooperation to develop the principle of social responsibility required to support activities and to participate, students level since the brand and products with known causes of this type to increase opportunities to the extent that the project supports. At this stage, our position, our organization and this small initiative of the project stakeholders, participants and students to benefit and to support the "diyerek, Linde Gas will continue cooperation with the university said.
Full digital black-and-white ultrasound system
İncekara the world standard in the health sector in the technological infrastructure to continue to win. Diagnosis and treatment systems, laboratory equipment, to offer the most advanced medical technologies to health care professionals. Representative of the pioneers of its development in the field of diagnostic ultrasound Aloka'nın new full digital black - white ultrasound tissue harmonic imaging system and 180 ° Prosound 6 features transvajinal probe is out. LCD monitor, high memory capacity, USB memory and ergonomic design with the users output high-level performance is live. Within a compact structure Prosound 6; ExPHDTM (Extended Pure Harmonic Detection), MFITM (Multi-Frequency Imaging), and limits, such as sharpening function as standard features are offered Prosound technologies. System options and various probes with very wide field of clinical practice is to the fore. Allows users to view each probta high rezolüsyonlu. Exceptional image quality of the class beyond the power Prosound technology brings a new standard in the field Prosound 6 classes.
High Performance LCD Monitors
LCD Monitor features, is set to optimize the ultrasound image. Extended Pure Harmonic Detection ExPHDTM Edge Enhancement (Smooth B) Function. Edge Enhancement Function as the top models are offered as standard. Digital Image Management, Integrated compact HDD, USB port, CD-R Drive (optional), Large Featured probes used in the top models Broadband Super High Density Probes suitable for Prosound 6. Wide Measurement Functions. Each area contains extensive measurement functions.
High Performance LCD Monitors
LCD Monitor features, is set to optimize the ultrasound image. Extended Pure Harmonic Detection ExPHDTM Edge Enhancement (Smooth B) Function. Edge Enhancement Function as the top models are offered as standard. Digital Image Management, Integrated compact HDD, USB port, CD-R Drive (optional), Large Featured probes used in the top models Broadband Super High Density Probes suitable for Prosound 6. Wide Measurement Functions. Each area contains extensive measurement functions.
Private health sector is waiting for the solution of urgent problems
Istanbul Chamber of Commerce (ITO) Chairman Murat Yalçıntaş, the private health sector of the Social Security Institution (SGK) provides services to patients living while waiting for the four main questions, said the immediate solution. In his written explanation on the subject Yalçıntaş, "contributed 30 percent share of the cost of inspection and participation agreement with major emergency-intensive care services cost difference" has requested to review the issues again. State's quality of health services offered at reasonable prices is the need of the social state principle Yalçıntaş emphasize, while offering this service between public and private organizations to create applications that inequality should be corrected are recorded. In recent years the right to benefit from the insured patients by private hospitals, health reform has been made in Yalçıntaş stating, "Private health institutions, state hospitals were forced to compete with the public has contributed to the increase in quality. This transformation process, no doubt the most important issues are not victims of the citizens. Like citizens from the public, and private health institutions should be able to receive services at the same quality at a reasonable price. However, this transformation is the great contribution of the private health sector, the last application for service with the risk of failure to meet real costs even have to face, "he spoke. President Murat Yalçıntaş, the private hospitals for treatment of patients SGK'lı receive 30 percent of the co-limit is too far away to meet the cost of real said. Public hospitals and private hospitals SGK members pay the cost of participation in the examination situation is unfair Yalçıntaş stating, "Hospitals participating in the examination fee received £ 3 from the patient, the private sector is $ 10. This application is contrary to the principles of equality and competition in its current form and punitive nature of the patient and the institution, "he spoke. Participation fee for the examination and a prescription to separate the two stages to implement the 3 +3 USD as Yalçıntaş indicating, "This significant saving in both drug costs and reduces the response of patients. $ 10 to the cost of participation in the current response of the patients in question is serious, "he said.
Branch agreements
Yalçıntaş, another topic that said the industry agreement. Large investments made with the latest technology services provider of patients SGK'lı agreements with industry to do that the İTO President Yalçıntaş, "our people, in some industries make large investments and the public interest considering the latest technology to serve the private health sector opportunities fully take advantage, but the agreement will be possible with the industry, "he spoke. Yalçıntaş, emergency and intensive care services also came to the stage stop, so the price of services should also be rearranged to highlight the "need for legal enforcement, such as emergency and intensive care services with many features of the difference can not be charged. Therefore, loss prevention, especially intensive care and should be fixed price, "he spoke. Yalçıntaş, 66 percent in the last five years to increase employment of the private health sector to shrink, to prevent the extinction and the arrangements to provide services to patients SGK'lı a moment ago that the conditions were recorded.
Branch agreements
Yalçıntaş, another topic that said the industry agreement. Large investments made with the latest technology services provider of patients SGK'lı agreements with industry to do that the İTO President Yalçıntaş, "our people, in some industries make large investments and the public interest considering the latest technology to serve the private health sector opportunities fully take advantage, but the agreement will be possible with the industry, "he spoke. Yalçıntaş, emergency and intensive care services also came to the stage stop, so the price of services should also be rearranged to highlight the "need for legal enforcement, such as emergency and intensive care services with many features of the difference can not be charged. Therefore, loss prevention, especially intensive care and should be fixed price, "he spoke. Yalçıntaş, 66 percent in the last five years to increase employment of the private health sector to shrink, to prevent the extinction and the arrangements to provide services to patients SGK'lı a moment ago that the conditions were recorded.
Private hospitals to apply to the Competition Council
Private Hospitals Association Chairman ImageEge Dr. Ulvi Unal, "Private Health Institutions and Investment Institutions" The decision about which health care institutions and private organizations that restrict the state institutions is that such a restriction is not told to. Private Hospitals Association of the Aegean Board of Directors, held in the Mövenpick Hotel dinner came together with members of the press.
Private Hospitals Association of the Aegean discussed here Chairman Dr. Ulvi Unal, Health Ministry is out of the "Special Health Authority and the Enterprise Investment" The decision about the private health provider organizations and state institutions and lead to unfair competition between institutions that took it forward. The decision of the private health institutions added buildings, new medical service units, health workers and technology-density medical devices in addition to restrictions such as that the state institutions to such a restriction in question is not, in which case the state institutions and private health organizations to generate unfair competition advocate Dr . Ünal, will go to the Competition Authority has made. Of foreign capital in the sector, it also does very little Dr. Ünal, said: "Unfortunately, very little foreign capital. At this time, many chains are in the hospital talk to foreign partnerships. However, these lower prices to foreign capital in chaos, hospitals may try to get on the cheap. But we do not leave a simple shoe. "Dr. Ünal, health sector institutions in providing services to banks and vendors are charged around 3 billion dollars was added to the word. Private Hospital Association Board of Ege, Vice President Dr. Özer Gürbüz, the Ministry of Health, Social Security Institution (SGK) in the treatment of members of private health institutions will pay for 30 percent of pay contribution limit practices such as private health institutions were told to lead to trouble. Have private health institutions and practices around the world into those who experienced the effects of global economic crisis, with private health institutions in Turkey will start in front of bankruptcy while Dr. Gürbüz, medical centers, has raised is to be closed. Dr. Gürbüz, said: "The country's resources will be wasted in this way. Seek foreign capital, you will not have their own capital. Progress zamanlarda crisis and the severance compensation will become more prominent, employee rights will be seriously damaged. Therefore, the private sector or in state hospitals buy it, let's work on behalf of the state, let's open the way health services or pre-applied to the state, let us open. Follow the terms of customizing it to be going. Both private, and she is not going to do printing. We dert 30 percent, 50 percent, but please let the system handle the rules. "Dr. Gürbüz, 70 percent of medical centers in the sector will be closed at a rate of 40 percent predict a narrowing of the future are said to occur. Aegean Private Hospitals Association of the Secretary-General would Vecdi Type, the Ministry of Health of the private health institutions into trouble because of the applications of the private sector is going from bad to worse, the problem is not money, the private sector's survival is recorded. Health workers in the transformation process that starts the cooperation with the states, everything goes the way that the type, you understand this change in practice and not remain the center said.
Private Hospitals Association of the Aegean discussed here Chairman Dr. Ulvi Unal, Health Ministry is out of the "Special Health Authority and the Enterprise Investment" The decision about the private health provider organizations and state institutions and lead to unfair competition between institutions that took it forward. The decision of the private health institutions added buildings, new medical service units, health workers and technology-density medical devices in addition to restrictions such as that the state institutions to such a restriction in question is not, in which case the state institutions and private health organizations to generate unfair competition advocate Dr . Ünal, will go to the Competition Authority has made. Of foreign capital in the sector, it also does very little Dr. Ünal, said: "Unfortunately, very little foreign capital. At this time, many chains are in the hospital talk to foreign partnerships. However, these lower prices to foreign capital in chaos, hospitals may try to get on the cheap. But we do not leave a simple shoe. "Dr. Ünal, health sector institutions in providing services to banks and vendors are charged around 3 billion dollars was added to the word. Private Hospital Association Board of Ege, Vice President Dr. Özer Gürbüz, the Ministry of Health, Social Security Institution (SGK) in the treatment of members of private health institutions will pay for 30 percent of pay contribution limit practices such as private health institutions were told to lead to trouble. Have private health institutions and practices around the world into those who experienced the effects of global economic crisis, with private health institutions in Turkey will start in front of bankruptcy while Dr. Gürbüz, medical centers, has raised is to be closed. Dr. Gürbüz, said: "The country's resources will be wasted in this way. Seek foreign capital, you will not have their own capital. Progress zamanlarda crisis and the severance compensation will become more prominent, employee rights will be seriously damaged. Therefore, the private sector or in state hospitals buy it, let's work on behalf of the state, let's open the way health services or pre-applied to the state, let us open. Follow the terms of customizing it to be going. Both private, and she is not going to do printing. We dert 30 percent, 50 percent, but please let the system handle the rules. "Dr. Gürbüz, 70 percent of medical centers in the sector will be closed at a rate of 40 percent predict a narrowing of the future are said to occur. Aegean Private Hospitals Association of the Secretary-General would Vecdi Type, the Ministry of Health of the private health institutions into trouble because of the applications of the private sector is going from bad to worse, the problem is not money, the private sector's survival is recorded. Health workers in the transformation process that starts the cooperation with the states, everything goes the way that the type, you understand this change in practice and not remain the center said.
Medical and pharmaceutical sectors in the February 23 elections İTO power unit formed
Elections in four years of Imageİstanbul Chamber of 23 February 2009 World Trade Center 9th this year and 10 be done in the hall. Each occupational group has its own elected representatives as a result of this selection 5, 7, 9 or 11 members of professional committees, four are on duty throughout the year. At present 87 Vocational Committee of the Istanbul Chamber of Commerce is located. Istanbul Chamber of Commerce (ITO) registered number of approximately 350,000 pieces of business, according to find different groups of commercial enterprises in list. In the last quarter of 2008 registered medical sector organizations to İTO European Union before the legislation 36-37 and 38 groups configured with the name again. 36. trade and services group providing laboratory equipment company, 37th the pharmaceutical and medical products group of producers and marketing companies, 38 In the group with dental and medical products has been a consolidation of related companies. This year, pharmaceutical and medical sectors where 37th women candidates in the list created a committee to represent the firm's activities before the 37th to çıkıyor.1.589 Medical group representing the industry familiar with the company manager Plastimed Ümit Özkaya, Multikan Health Products Company manager Hakan Memis, Kurtsan Medical Industry Trade Co. Chairman Meltem Kurtsan, Eczacıbaşı Zentiva General Manager Elif Çelik and Rose Ecza Store AŞ manager Güner Zeynep Yüceer together by coming into the selection list of candidates is created. Medical sector came to be used in, except where the three female candidates list manager, with the majority of women also represent a first İTO elections. Candidates for election into why as the economic problems in our country right now and that the solution to the shortage of non-governmental organizations showed declining role. The other objectives in the pharmaceutical and medical sector, all civil society organizations active on a call to create a platform to bring the sector to improve interpersonal communication and cooperation as açıklıyorlar.37. candidates in the group, working in an open and transparent administration at the beginning of the principles, the pharmaceutical and medical field will give an equal representation of space; administration during local and foreign companies are also represented in a balanced manner is expressed. Important problems that the pharmaceutical and medical products sector, problems lasting solutions to be professional committee duties between the relevant laws, statutes and regulations to examine the commercial life of the affected applications to investigate consumer complaints to assess and occupation of any proposal İTO Board or the Assembly İTO 'is introduced in.
Subscribe to:
Posts (Atom)
